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 Nitric oxide (NO) is one of the important biological molecules which has functions in 
neurotransmission, vasodilation, and immune responses. However, excess levels of NO have 
been associated with neurodegenerative and inflammation-related diseases. Nitric oxide 
synthase (NOS) is the enzyme that catalyzes the synthesis of NO from L-arginine in biological 
systems, and has been a potential target for inhibition. Three isoforms of NOS exist in 
mammalian systems: neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS 
(iNOS). While nNOS and eNOS are named according to where they are expressed, iNOS is 
named by its inducible expression. The structures of the active sites of the three isoforms are 
determined to be similar.  
This has been posing a challenge in the development of NOS inhibitors, because 
inhibition of eNOS has been shown to ultimately lead to hypertension and atherosclerosis. To 
overcome this, researchers have examined a wide variety of possible inhibitors. Binding of the 
inhibitors to non-human NOS isoforms was often studied by crystallography and by 
mutagenesis studies. However, none of the inhibitors have been approved for clinical 
applications. 
 In this study, expression systems for different forms of human NOS isozymes were 
investigated. This involved molecular cloning of expression vectors for human full-length NOS 
isozymes and their oxygenase domains. It has been demonstrated that preparations of 
oxygenase domains is easier giving good yields due to their smaller size compared to the 
holoenzymes. After confirmation of the molecular cloning of the expression vectors by 
restriction enzyme digestions and by DNA sequencing, expression and purification of the 
oxygenase domains were attempted. As N-terminal histidine tags were present in the 
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oxygenase domains, protein purifications were carried out in nickel affinity columns. For the 
human nNOS oxygenase domain with the CaM-binding region, the protein was also purified 
by a glutathione column as a second purification step with the addition of glutathione S-
transferase-tagged calmodulin (GST-TEV-CaM). It is shown that the oxygenase domains are 
well expressed but further protein purification is required.  
Lastly, expression and purification of GST-TEV-CaM were developed and optimal 
cleavage reaction conditions of GST-TEV-CaM by TEV protease were studied. From this 
study, optimal cleavage reaction condition is identified for GST-TEV-CaM which can be used 
in the purification of various forms of human NOS isozymes. These studies will allow 
optimization of purification of human forms of NOS oxygenase domains and holoenzymes for 
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1.1 Nitric Oxide in Biological Systems 
 Nitric oxide (NO) is a highly reactive free radical, which consists of a nitrogen and an 
oxygen atom (Bretscher et al., 2003). In biological systems, it is an essential molecule that 
participates in various physiological processes. In the nervous system, it is produced as a 
signaling molecule for neurotransmission. It is also found in endothelial cells, in which it is 
involved in the regulation of blood pressure. Last but not least, it plays an important role in the 
immune system by being present in high amounts and exhibiting cytotoxic effects against 
infections and tumour cells (Joubert & Malan, 2011).  
Our body is able to produce this molecule and its production appears to require tight 
regulation, as insufficient or excessive production demonstrates pathological role in several 
disease states. Low concentrations of NO in neurons and endothelial cells have been related to 
hypertension, atherosclerosis, and other cardiovascular diseases. On the other hand, excess NO 
has been observed in patients with neurodegenerative diseases such as Parkinson’s and 
Alzheimer’s diseases (Xue et al., 2010). In the immune system, overproduction of NO seems to 
be linked to inflammation, immune-type diabetes, and rheumatoid arthritis (Garcin et al., 2008). 
Due to its roles mentioned, there is significant interest in finding ways to control NO 
production.  
1.2 Nitric Oxide Synthase 
Nitric oxide synthase (NOS) is the enzyme that is responsible for the synthesis of NO 




1.2.1 NOS Isoforms 
 Three isoforms of NOS are identified in mammalian systems, which are neuronal NOS 
(nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS). nNOS carries out NO synthesis 
in the central nervous system, while eNOS takes part in the regulation of smooth muscle 
relaxation. iNOS received its term ‘inducible’ from its inducible expression in macrophages in 
contrast to nNOS and eNOS, whose expressions are constitutive (Joubert & Malan, 2011). 
Another feature that nNOS and eNOS share is that their enzymatic reactions are subject to 
formation of complexes with Ca
2+
/calmodulin. Calmodulin (CaM) is a calcium-sensing protein 
in cells, which can bind to and activate NOS. iNOS is quite different from nNOS and eNOS, 
whose activity is independent of calcium content in cells. The three isoforms, having different 
features, also show to derive from different genes and to have different subcellular 
localizations and inhibitor binding. Nonetheless, about 50% amino acid sequence homology 
was seen between the human isoforms (Alderton et al., 2001). 
1.2.2 NOS Structure 
 Despite the differences in their primary amino acid sequences, the three isoforms were 
observed to be comprised of similar components. They are homodimeric proteins, in which 
each monomer consists of two domains (Joubert & Malan, 2011). The N-terminal domain 
displays oxygenase activity that has binding sites for a heme, tetrahydrobiopterin (BH4), and its 
substrate, L-arginine. The C-terminal domain is a reductase domain which contains sites for 
flavin mononucleotide (FMN), flavin-adenine dinucleotide (FAD), and nicotinamide adenine 
dinucleotide phosphate (NADPH). The two active domains are connected by a calmodulin 
binding motif (Alderton et al., 2001).  
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 The active site is found in the N-terminal oxygenase domain, to which heme and BH4 
are bound, and to which electrons from the reductase domain are finally transferred. Crystal 
structures of the isoforms reveal high conservation of residues in the active sites of all three 
isoforms, and this has posed a challenge in the design of isoform-selective inhibitors of NOS 




1.2.3 NO Synthesis Reaction 
For NO synthesis, the two domains that are present in each monomer have distinctive 
roles. The reductase domain, as its name suggests, reduces the other domain upon firstly 
accepting a hydride ion from NADPH producing NADP
+
. Then, electrons are transferred from 
FADH2 to FMNH·. FMNH2 in the reductase domain lastly donates the electrons to the heme 
iron in the oxygenase domain where NO synthesis occurs (Alderton et al., 2001).  
Figure 1.1 Illustration of the structures of NOS isoforms. This figure also indicates the 
locations of PSD-95 discs large/ZO-1 homology domain (PDZ), zinc-ligating cysteines (Zn), 





The oxygenase domain generates NO upon conversion of L-arginine into L-citrulline. 
The domain hydroxylates L-arginine at one of the guanidino nitrogens, using molecular oxygen 
(O2) as co-substrate. This reaction forms the intermediate, N
ω
-hydroxy-L-arginine (NHA). The 




1.3 NOS Inhibitors 
 Due to their aforementioned pathological effects by NO overproduction, nNOS and 
iNOS have been therapeutic targets for inhibition. However, inhibition of eNOS results in low 
levels of NO, which can lead to hypertension and other cardiovascular diseases. For these 
Figure 1.2 Overall NOS reaction 
Figure 1.3 NO synthesis reaction at the oxygenase domain 
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reasons, studies on the development of isoform-selective inhibitors have been extensively 
performed, and numerous inhibitors have been generated. Based on their structures, the 
inhibitors are divided into two groups: amino acid-based inhibitors and non-amino acid-based 
inhibitors (Salerno et al., 2002).  
1.3.1 Amino acid-based Inhibitors 
 L-Arginine analogues are one of the studied amino acid-based inhibitors, as they tend 
to be less toxic and potent in vivo with their similarity in structure to L-arginine. One 
disadvantage of these inhibitors was that they do not show high selectivity (Bretscher et al., 
2003). Another example of amino acid-based inhibitors is N-nitro-L-arginine (L-NNA) (Fig. 
1.4 (a)). This compound was demonstrated to inhibit NOS activity well but studies also 
revealed moderate selectivity. As well, it showed to have low solubility at neutral pH (Vitecek 





2-NH2 were made whose selectivities for nNOS were high. 
The study also demonstrated that dipeptides containing basic amine side chains were effective 
against and selective for nNOS by forming non-covalent interactions (Salerno et al., 2002). 
However, being also selective for eNOS, the dipeptides were evaluated to be unsafe for clinical 
trials.  
                                                                               
  








1.3.2 Non-Amino acid-based Inhibitors 
 Non-amino acid-based inhibitors were also examined for design of NOS inhibitors 
with high selectivity and potency. Results from studies on these inhibitors presented that 
inhibition of NOS does not necessarily require the amino acid moiety. This group could be 
further broken down into two subgroups, the amidinic and heterocyclic compounds. Amidinic 
compounds, which encompass guanidines, isothioureas, and amidines, had efficient NOS 
inhibition (Salerno et al., 2002). Their structures could mimic that of L-arginine, which showed 
different selectivities with their diverse moieties. Similarly, studies demonstrated that 
heterocyclic compounds, such as indazoles, and imidazoles, could effectively inhibit NOS 
isoforms with excellent selectivity. However, a general relationship between inhibitor 
structures and their activities on the isoforms could not been identified so far. This seemed to 
be because the structures vary widely and the inhibitors have different mechanisms of action. 
As well, despite in-depth research, no inhibitor has been approved for clinical applications 
(Maddaford et al., 2009). 
      
 
  





1.4 Challenges in the Development of NOS Inhibitors 
 Challenges in the development of isoform-selective NOS inhibitors include similar 
active sites among the isoforms, as well as difficulty in defining a structure-activity 
relationship of NOS inhibitors, as mentioned before. Furthermore, advancement in the 
development of effective NOS inhibitors appears to be slow due to insufficient information on 
inhibitor binding to NOS isoforms. Binding of NOS inhibitors has often been examined using 
crystallography, but several limitations on the technique have been suggested. Some examples 
are ambiguities with the identity or the position of a compound in the binding site, and the fact 
that biophysical information on the inhibitor binding, such as binding enthalpies and 
interaction types, cannot be obtained from crystal structures (Maddaford et al., 2009). There 
have been cases of inhibitor studies where crystal structures suggested promising bindings of 
inhibitors but other binding studies demonstrated poor activities of the inhibitors.  
 Studies on non-human NOS isoforms also seem to present a challenge. For many 
binding studies of NOS inhibitors, several mammalian NOS isoforms were used such as rat 
nNOS, bovine eNOS, and murine iNOS. Rat nNOS has been comprehensively studied due to 
its 90% sequence identity to human nNOS and its efficient purification method. However, 
other studies have shown that rat nNOS has different binding affinities to certain inhibitors 
from that of human nNOS, although the affinities for L-arginine were similar (Fang et al., 
2009). 
1.5 Anchored Plasticity Approach 
 In order to solve the problem with conserved active sites, Garcin et al. (2008) proposed 
a systematic and logical approach in investigating isoform-selective inhibitors, called the 
anchored plasticity approach. This approach analyzes inhibitor binding and enzyme structural 
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changes to discover isoform-selective binding modes. In this approach, an inhibitor is set or 
anchored in a conserved active site and then, upon addition of rigid substituents to the structure, 
formation of a novel isoform-specific pocket is explored. In the study by Garcin et al., this 
approach was demonstrated with an aminopyridine compound, shown in Figure 1.6 (a). From 
IC50 results, this compound was more potent to iNOS than to eNOS. Crystal structures revealed 
that while the amidine moiety of the compound binds and stacks with the heme in the active 
site, its side chain causes a conformational change in iNOS and creates a novel pocket. This 
seemed to have occurred by the movement of outer residues that interact with the residues in 
the active site. In iNOS, the residue that interacts with the active site residues, referred as the 
first-shell residue, was arginine, which seems to be able to freely rotate and form the novel 
pocket and additional hydrogen bonds (Fig. 1.6 (b)). However, in eNOS, the rotation of 
arginine in the first shell was seen to be restricted by third-shell residues, leucine and 
isoleucine, which are different from those in iNOS (Table 1.1). This was proposed to prevent 
eNOS from creating a pocket with additional hydrogen bonds decreasing its binding affinity. 
Similar results were observed with an iNOS mutant that is composed of eNOS third-shell 













Table 1.1 Major residues that participate in creation of isoform-specific pockets in NOS. 
This table shows isoform-specific residues in the third shell that are different between NOS 










Mouse iNOS Glu371 Gln257 Tyr341 Arg260 Arg382 Thr277 Phe280 Leu299 
Human iNOS Glu377 Gln263 Tyr347 Arg266 Arg388 Asn283 Phe286 Val305 
Bovine eNOS Glu362 Gln248 Tyr332 Arg251 Arg373 Asn268 Ile271 Leu290 
Human eNOS Glu360 Gln246 Tyr330 Arg249 Arg371 Asn266 Ile269 Leu288 
Figure 1.6 Aminopyridine compound whose NOS binding was studied by Garcin et al. (a) 
and a schematic diagram illustrating movement of residues in human Δ70 iNOS and 
eNOS upon its binding (b).  Unhighlighted Gln and Arg are first shell residues while those in 
orange are second shell residues. Third shell residues are highlighted in green. In iNOS, 
binding of the compound induces Gln-open conformation which leads to rotations of Arg and 
Asn. eNOS cannot form the Gln-open conformation due to the presence of third shell residues, 




1.6 Research Objectives 
 The research objectives of this study were to produce human isoforms of NOS and 
study their interactions with NOS inhibitors for better understanding of isoform selectivity that 
will be useful in the development of NOS inhibitors with enhanced selectivity.  The research 
aimed at testing the possibility that isoform specific binding to human NOS isozymes has been 
overlooked because of the general use of non-human mammalian recombinant enzymes. Most 
of the published studies have used recombinant bovine eNOS and rat nNOS, in addition to 
human iNOS. For this reason, new expression systems were developed in the lab for the human 
NOS isozymes. The investigation focussed on characterizing the new expression systems with 
the ultimate goal of using them to test the anchored plasticity approach for the identification of 
NOS isoform specific inhibitors.     
In the past, various host cells have been used for the expression of mammalian NOS 
enzymes including yeast, insect cells, and bacteria (Roman et al., 1995). Of all the host cell 
systems used, it was discovered that bacterial cells gave the best results. Our lab has produced 
the human iNOS, rat nNOS and bovine eNOS but never the human forms of nNOS and eNOS.  
Our experience showed that the expression and purification of these enzymes was very labour 
intensive and gave low yields of recombinant protein. Accordingly, it was decided to try a 
parent plasmid with a stronger promoter in the hope of getting better expression and yields of 
the protein. Most P450-like proteins including NOS have been expressed in E. coli using the 
pCWori expression vector. pCWori is not a strong expression vector and it was decided to try 
using a vector with a strong promoter from the pET series.  
Each of the active sites in NOS isozymes are composed of a dimer consisting of 
oxygenase domains from two NOS subunits. Previous studies have shown that active site 
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dimers can be generated from recombinant expression of the oxygenase domain alone 
(McMillan & Masters, 1995).   Also, recombinant NOS oxygenase domain expression systems 
generally provide higher yields and require less complex expression and purification 
procedures (Rafferty et al., 1999). Consequently, for the initial screening of inhibitors that bind 
to the enzyme active site, expression systems consisting of the oxygenase domains for each of 
the three isoforms were generated.  Expression systems for the human NOS holoenzymes will 
also be required to assay the enzymes activity in the presence of any lead compounds from the 
oxygenase investigation.   
 In order to further functionalize the recombinant forms of the NOS enzymes, 
expression systems for all three enzymes were generated that consisted of the catalytic 
oxygenase domain as well as the downstream calmodulin (CaM) binding domain that resides in 
between the oxygenase and reductase domains of NOS isozymes. These constructs were 
referred to as oxyCaM proteins and the CaM-binding region that could be used as an additional 
affinity tag for purification of the oxygenase domains and for protein immobilization. Chapter 
2 describes the subcloning and characterization of all nine constructs.    
 Chapter 3 describes the initial attempts to express and purify the oxygenase domains of 
all three isoforms of human NOS.  In chapter 4, an expression vector for GST-TEV-CaM was 
constructed and the recombinant protein was characterized. This fusion protein could be used 
in purification of NOS isoforms and oxygenase domains using a glutathione column. The 
expression vector for GST-TEV-CaM was created such that a Tobacco Etch Virus (TEV) 
protease site would be present between GST and CaM for removal of GST portion. 
Accordingly, different reaction conditions for optimization of the GST-TEV-CaM cleavage 




Subcloning of Human NOS Isoforms and Oxygenase Domains 
2.1 Introduction 
In this chapter, molecular cloning of human NOS oxygenase domains and holoenzymes 
is described. Not all but most of the human NOS isoforms and oxygenase domains were cloned 
into pDS-78 while others were in a pCWori vector. pDS-78 was a modified version of the 
kanamycin resistant pET28a vector which has a cleavage site for TEV protease incorporated 
four amino acids after the N-terminal hexahistidine tag. The cleavage site, which is ENLYFQG, 
was added for removal of the N-terminal hexahistidine tag. pCWori, which contains an 
ampicillin resistance gene, is a commonly used vector for expression of NOS in E. coli and the 
protein expression from a pET vector was attempted in this study (Roman et al., 1995). A 
major difference between pCWori and pET is the promoter which controls mRNA 
transcription for the recombinant protein. In pCWori, the expression of the recombinant protein 
is under control of a tac promoter, a hybrid promoter of -35 region of a trp promoter and -10 
region of a lacUV5 promoter. The combination of the two regions is known to be a favourable 
binding site for E. coli RNA polymerase. Instead, pET has a T7 promoter which T7 RNA 
polymerase specifically recognizes (Zelasko et al., 2013).  
 The construction of phnNOSox, pheNOSox, and pCWori-hiNOSox was carried out by 
Jenna Collier (UW Co-op student) and Maggie Zhou (BSc. U of Waterloo, Summer student). 
The molecular cloning of phnNOSoxyCaM was carried out by the candidate, and that of 
pheNOSoxyCaM was performed by Kevin Pottruff (BSc. U of Waterloo). pCWori-
hiNOSoxyCaM was created by Simon Guillemette (BSc. U of Waterloo, Summer student). The 
molecular cloning of phnNOS was carried out by Edmund Luk (UW Co-op student), while that 
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of pheNOS was done by Ryan Cho (BSc. U of Waterloo, Summer student). Jenna Collier (UW 
Co-op student) and Maggie Zhou (BSc. U of Waterloo, Summer student) also accomplished 
the construction of phiNOS. 
2.2 Methods 
2.2.1 phnNOSox 
 phnNOSox was the expression vector for the human nNOS oxygenase domain without 
CaM-binding region (hnNOSox). This vector contained the human nNOS oxygenase domain 
whose amino acid sequence ended just before the CaM-binding region in pDS-78. The cloning 
was accomplished by Polymerase chain reaction (PCR) amplification of the human nNOS 
oxygenase domain from the full-length human nNOS. The forward and reverse primers used 
were, respectively: 
HnoxyFor 5’ GGAATTCATATGGAGGATCACATGTTCGGTG 3’ 
HnoxyStop 5’ ATCGATAAGCTTATCAGGTGCCTTTCCAGACATGCGTGTTCC 3’ 
NdeI and HindIII sites were present in the primers at 5’- and 3’-ends, respectively, and so were 
digested for insertion of the PCR product into pDS-78.  
2.2.2 pheNOSox 
 Human eNOS oxygenase domain without the CaM-binding regioin (heNOSox) was 
cloned into pDS-78 as well and the cloning was done similarly to phnNOSox. heNOSox gene 
was PCR amplified and NdeI and HindIII sites that were present in the forward and reverse 
primers, respectively, were also incorporated by PCR.  
eNoxFor 5’ GCGGAATTCATATGCACCACCACCACCACCACATGGGCAACTTGAAGA 
GCGTGGCC 3’ 




 pCWori-hiNOSox was the expression vector for human Δ70 iNOS oxygenase domain 
without the CaM-binding region (hiNOSox) in which residues 1 – 70 were removed. This was 
because the region seems to be prone to proteases and hold rare codons. For its construction, a 
stop codon was introduced just downstream of human Δ70 iNOS oxygenase domain in the 
holoenzyme that is in the ampicillin resistant vector, pCWori by two-stage PCR site-directed 
mutagenesis (Wang & Malcolm, 1999). This mutagenesis protocol has an additional PCR stage 
to the original PCR site-directed mutagenesis protocol. Prior to the PCR stage with both 
forward and reverse primers that have the intended mutation, two PCRs, one with only the 
forward primer and another one with the reverse primer, are carried in separate tubes for 1 to 5 
cycles. Afterwards, the two samples are mixed and are subjected to 15 PCR cycles as in the 
original PCR site-directed mutagenesis. Then, one adds the restriction enzyme, DpnI, which 
digests only methylated plasmids, the template, and uses the sample for bacterial 
transformation. In pCWori-hiNOSox, a HindIII site was incorporated at the 3’-end of the stop 
codon. As an additional HindIII site was present just downstream of the reductase domain, the 
mutagenesis could be confirmed by HindIII digestion, in which two fragments of 6.3 kb and 
1.9 kb were generated. Then, HindIII digestion and a subsequent ligation reaction were 
performed for removal of the reductase domain. The removal was verified by HindIII digestion 
where a fragment of 1.9 kb was absent.  
2.2.4 phnNOSoxyCaM 
 phnNOSoxyCaM, the expression vector for human nNOS oxygenase domain with the 
CaM-binding region (hnNOSoxyCaM), was also made by two-stage PCR site-directed 
mutagenesis. The template used in the PCR amplification was the pDS-78 vector containing 
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the full-length human nNOS and a stop codon and an EcoRI were incorporated at the 3’-end of 
CaM-binding region. This was accomplished with the forward and reverse primers: 
HnNOSOxCamF 5’ GGGGCAGGCTATGGCCTAGAATTCGAAAGCGACCATCCTCTAT 
GCC 3’ 
HnNOSOxCamR 5’ GGCATAGAGGATGGTCGCTTTCGAATTCTAGGCCATAGCCTGC 
CCC 3’ 
After plasmid purification, the mutagenesis was verified by EcoRI digestion from which two 
DNA bands of 7.6 kb and 2.3 kb were seen.  
2.2.5 pheNOSoxyCaM 
 For the expression vector coding human eNOS oxygenase domain with the CaM-
binding region (heNOSoxyCaM), full-length human eNOS in pDS-78 was also subjected to 
PCR amplification for addition of a stop codon downstream of CaM-binding region by two-
stage PCR site-directed mutagenesis. As well, a HindIII restriction site was added at the 3’-end 
of the stop codon to be used for confirmation of the intended mutation with the following 
primers: 
HeNOSoxCamF 5’ CATGGGCACGGTGATGGCGTAAGCTTTGAAGGCGACAATCCTGT 
ATGGCTCC 3’ 
HeNOSoxCamR 5’ GGAGCCATACAGGATTGTCGCCTTCAAAGCTTACGCCATCACCG 
TGCCCATG 3’ 
HindIII digestion of a candidate vector generated an 8.8 kb and a 2.2 kb fragment which 





 The expression vector for human Δ70 iNOS oxygenase domain with the CaM-binding 
region (hiNOSoxyCaM), pCWori-hiNOSoxyCaM, was also constructed by two-stage PCR 
site-directed mutagenesis. Full-length human Δ70 iNOS in an ampicillin resistant pCWori 
vector was taken and a stop codon and a HindIII restriction site were introduced downstream of 
CaM-binding region.  The forward and reverse primers used for the mutagenesis were: 
HiNOSoxCamF 5’ GACAATGGCGTCCCGAGTCTGAAGCTTCATCCTCTTTGCGACAG 
AGACAG 3’ 
HiNOSoxCamR 5’ CTGTCTCTGTCGCAAAGAGGATGAAGCTTCAGACTCGGGACGCC 
ATTGTC 3’ 
The success of the mutagenesis was confirmed by HindIII digestion. The digestion resulted in a 
1.8-kb and a 6.4-kb fragment, as expected.  
2.2.7 phnNOS 
 pDS-78 vector containing the full-length human nNOS (hnNOS) coding region was 
prepared by one-step sequence- and ligation-independent cloning (SLIC) method  (Jeong et al., 
2012). This method involved PCR amplification of the full-length human nNOS. The primers 
used were: 
HNfullfor 5’ CTTGTATTTCCAGGGCCATATGGAGGATCACATGTTCGGTGTTCAGC 3’ 
HNfullrev 5’ CAGCAGCTTACGATCTTCTTCCATATTAGGAGCTGAAAACCTCATCGG 
TGTCT 3’ 
The forward and reverse primers used were designed so that regions homologous to NdeI-
cleaved vector ends are incorporated to the ends of the PCR product. Afterwards, the PCR 
product and cleaved vector were mixed at an insert-to-vector ratio of 2:1. One also added, to 
the mixture, T4 polymerase which has 3’ to 5’ exonuclease activity and creates 5’ overhangs, 
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and incubated for 3.5 minutes at room temperature. This mixture was then used in bacterial 
transformation by heat shock in which DNA gaps would be repaired and the cloning would be 
completed.  
2.2.8 pheNOS 
 The full-length human eNOS (heNOS) was cloned into pDS-78. Initially, the full-
length human eNOS coding region was PCR amplified with the following primers: 
Hefullfor 5’ CTTGTATTTCCATATGGGCAACTTGAAGAGCGTGGCCCAGGAG 3’ 
HefullrevEcoRI 5’ GCGGAATTCTCAGGGGCTGTTGGTGTCTGAGCCGGG 3’ 
While an NdeI site was already present in the PCR product amplified, the reverse primer in the 
PCR had an EcoRI site to add to the 5’ end. The PCR product as well as the vector, pDS-78, 
were then digested with NdeI and EcoRI, and were mixed in a ligation reaction. Subsequent 
bacterial transformation by heat shock was performed. This resulted in the full-length human 
eNOS coding region to be in the kanamycin resistant pDS-78 vector. Also, the human eNOS 
would be hexahistidine-tagged at its N-terminal end, when expressed in E. coli cells. 
2.2.9 phiNOS 
 phiNOS, full-length human Δ70 iNOS (hiNOS) in pDS-78, was made digestion and 
ligation procedures. For its cloning, the full-length human Δ70 iNOS coding region was 
isolated from ampicillin resistant pCWOri vector by double digestion with NdeI and HindIII 
restriction enzymes. The region of interest was cut out such that its N-terminal hexahistidine 
tag from pCWOri vector was retained. Subsequently, it was inserted into a pDS-78 vector. This 




2.3 Results  
2.3.1 Expression Vectors for Human NOS Oxygenase Domains without CaM-binding 
region 
Digestion of phnNOSox with NdeI and HindIII resulted in a 2.2-kb fragment which 
was the human nNOS oxygenase domain without the CaM-binding region and a 5.3-kb 
fragment, the pDS-78 vector. As well, complete sequencing of the oxygenase domain verified 
its subcloning without any mutations. From this result, it could be confirmed that the human 
nNOS oxygenase domain was successfully inserted into pDS-78 vector (Figure 2.1). (please 




Figure 2.1 Vector map of phnNOSox coding human nNOS oxygenase domain without 
CaM-binding region. This figure is showing features present in the phnNOSox vector, such as 
the kanamycin resistant gene and lacI gene. It is also showing restriction enzyme sites that one 




The molecular cloning of human eNOS oxygenase domain without the CaM-binding region 
was verified by double digestion with NdeI and HindIII as well. The double digestion 
generated the 1.5-kb insert and 5.3-kb vector. The insert was also fully confirmed by 
sequencing. (Figure 2.2) 
 
Figure 2.2 Vector map of pheNOSox coding human eNOS oxygenase domain without 
CaM-binding region.  The insert was subcloned into kanamycin resistant pDS-78 vector at 
NdeI and HindIII sites, which are shown in this figure. Accordingly, N-terminal histidine tag 




Digestion of pCWori-hiNOSox with HindIII did not show a fragment of 1.9 kb which 
confirmed the removal of the reductase domain with the CaM-binding region and relegation of 
the vector. Also, the removal was confirmed by sequencing. However, the DNA sequences 1 – 
165 and 1177 – 1206 were not examined and can be sequenced with primers pCWOri-fr and 
1000iNOSfr. (please refer to the Appendix for DNA sequences) 
 
Figure 2.3 Vector map of pCWori-hiNOSox coding human Δ70 iNOS oxygenase domain 
without CaM-binding region. In pCWori-hiNOSox, human Δ70 iNOS oxygenase domain is 
in a pCWori vector. The domain in this vector is histidine-tagged at its N-terminus and does 
not contain a TEV protease cleavage site between the domain and the tag. This vector has an 




2.3.2 Expression Vectors for Human NOS Oxygenase Domains with CaM-binding region 
For phnNOSoxyCaM, the presence of a mutation could be recognized by digestion of 
the vector with EcoRI. The digestion generated two fragments of 2.3kb and 7.6 kb. The insert 
was fully sequenced and a mutation at G726W was found.  
 
Figure 2.4 Vector map of phnNOSoxyCaM coding human nNOS oxygenase domain with 
CaM-binding region. A stop codon and an EcoRI restriction site were introduced to phnNOS 
for expression of human nNOS oxygenase domain with CaM-binding region. Accordingly, it 
contains features present in phnNOS, such as N-terminal histidine tag, TEV protease site, and 
the kanamycin resistance gene, but protein translation of the nNOS would stop just 




Digestion of pheNOSoxyCaM with HindIII produced a 2.1-kb and a 6.8-kb fragment. This 
result demonstrated that the intended mutation, the addition of a stop codon and a HindIII site, 
occurred successfully. The insert was also verified by sequencing where no mutation was 
found. 
 
Figure 2.5 Vector map of pheNOSoxyCaM coding human eNOS oxygenase domain with 
CaM-binding region. Human eNOS oxygenase domain with CaM-binding region is in the 
kanamycin resistant pDS-78 vector. It was created by addition of a stop codon and a HindIII 




For pCWori-hiNOSoxyCaM, the vector was digested with HindIII. As a result, a 1.8-kb and a 
6.4-kb fragment were seen and the intended mutation could be identified by sequencing. From 
these results, it could be confirmed that the vector was mutated as planned. Most part of the 
oxygenase domain with CaM-binding region was sequenced except the initial part (1 – 165) 
that needs to be sequenced with primer pCWOri-fr. 
 
Figure 2.6 Vector map of phiNOSoxyCaM coding human Δ70iNOS oxygenase domain 
with CaM-binding region. Similarly to pCWori-hiNOSox (Figure 2.3), the human Δ70 iNOS 
oxygenase domain with CaM-binding region is present in a pCWori vector. Accordingly, the 
vector includes an ampicillin resistance gene. The oxygenase domain has an N-terminal 
hexahistidine tag but a TEV protease site is absent in between. For its construction, full-length 
human Δ70 iNOS in pCWori was mutated such that a stop codon and a HindIII are present 
downstream to CaM-binding region.  
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2.3.3 Expression Vectors for Human NOS Isoforms 
 The insertion of full-length human nNOS was confirmed by single digestions with 
BglII and HindIII. The expected band patterns were seen and its vector map is shown in Figure 
2.7. The insert was confirmed by sequencing except DNA sequences 2392 – 2562 that needs to 
be sequenced by the primer hnNOSfr2600. Sequencing results showed that in comparison to 
UniProt sequence, mutations have occurred at E583Q, G726W, and G1355R. Nonetheless, 
mutation E583Q was questionable since it was not seen in the sequencing result for 




Figure 2.7 Vector map of phnNOS coding human full-length nNOS. The full-length human 
nNOS was inserted without the use of restriction enzymes through the one-step sequence- and 
ligation-independent cloning method into kanamycin resistant pDS-78 vector. The cloning into 
pDS-78 added an N-terminal hexahistine tag to the insert and a TEV protease site between the 
tag and the insert. This vector map is showing restriction enzyme sites used for confirmation of 
presence of the insert.  
The vector map of pheNOS is shown in Figure 2.8. Single digestion with NcoI and double 
digestion with NdeI and EcoRI verified successful molecular cloning of the full-length human 
eNOS in pDS-78. NcoI digestion produced a 3.4-kb and a 5.5-kb fragment, while double 
digestion with NdeI and EcoRI yielded two fragments with sizes of 3.6 kb and 5.4 kb, as 
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expected. Sequencing of pheNOS also confirmed the presence of the holoenzyme in the vector. 
DNA sequences 1375 – 1524 just need to be sequenced by primer heNOS1280fr. 
 
Figure 2.8 Vector map of pheNOS coding human full-length eNOS. This vector holds the 
full-length human eNOS in pDS-78. For its construction, the human eNOS was cloned into 
pDS-78 at NdeI and EcoRI sites. Upon insertion into pDS-78, same features, N-terminal 
histidine tag and a TEV protease site, were added to eNOS, as in phnNOS (Figure 2.7). This 




phiNOS vector was digested with NdeI and HindIII, restriction enzymes for confirmation of 
the presence of the insert in the vector. Upon the double digestion, one was able to see the 3.3-
kb insert and 5.3-kb vector (Figure 2.9). The presence of the insert was also verified by 
sequencing with primers 505iNOSfr and 3496iNOSfr, but a thorough sequencing of the whole 
insert was not performed.  
 
Figure 2.9 Vector map of phiNOS coding human Δ70iNOS. Human Δ70iNOS was 
subcloned into kanamycin resistant pDS-78. As a result, same features, as in phnNOS (Figure 
2.7) were added to human Δ70iNOS. There is an additional hexahistidine tag at the N-terminus 
















phnNOSox nNOSox p511 pDS-78 T7 Present Complete 
pheNOSox eNOSox p513 pDS-78 T7 Present Complete 
pCWori-
hiNOSox 
Δ70 iNOSox p508 pCWori tac Absent Incomplete 
phnNOSoxyCaM nNOSoxyCaM p525 pDS-78 T7 Present Complete 





p524 pCWori tac Absent Incomplete 
phnNOS nNOS p522 pDS-78 T7 Present Incomplete 
pheNOS eNOS p523 pDS-78 T7 Present Incomplete 
phiNOS Δ70 iNOS p510 pDS-78 T7 Present Incomplete 
Constructs in pDS-78 vector are kanamycin resistant while those in pCWori vector are 
ampicillin resistant.  
 
2.4 Discussion 
 Upon constructions of expression vectors for various forms of human NOS, different 
molecular cloning methods could be examined. Human NOSox constructs, phnNOSox, 
pheNOSox, and phiNOSox, were created by the digestion and ligation method. This method 
was useful in that restriction enzymes are known to be very active and specific for generation 
of sticky ends. However, compared to the SLIC method, the method can take longer time with 
both digestion and ligation reactions, since the SLIC method does not involve a ligation 
reaction that can take overnight. In addition, for phnNOSox and pheNOSox, their cloning 
method was prone to mutation, since the inserts were PCR amplified with addition of flanking 
restriction enzyme sites.  
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For human NOSoxyCaM constructs, two-stage PCR site-directed mutagenesis was used 
for introduction of stop codons downstream to the CaM-binding regions. An advantage of this 
method is that it is more efficient than the original PCR site-directed mutagenesis due to its 
separate forward and reverse primer PCR reactions. Although it is an additional step, upon 
separate single-primer reactions, there is no competition to primers for annealing sites (Wang 
& Malcolm, 1999). Yet, it is possible to introduce unintended mutations with this method, as 
the whole plasmid was PCR amplified.  
Another molecular cloning method that was employed was the SLIC method for sub-
cloning of the full-length nNOS into pDS-78. It was advantageous as the ligation step was 
omitted and instead, the vector and the insert were incubated with T4 DNA polymerase for 3.5 
minutes (Jeong et al., 2012). However, this method also suffers from the disadvantage that 
unintended mutations can occur upon PCR amplification of the insert.  
Analysis of sequencing results revealed that cloning methods involving PCR 
amplification introduced unintended mutations in the inserts. In heNOSoxyCaM, ATG was 
deleted by which the following codon was shifted to its position. This resulted in a mutation 
from a methionine to an alanine at amino acid position 514. This amino acid position was 
found to be the last amino acid in heNOSoxyCaM and to be not within any of the binding sites. 
However, a crystal structure that includes the amino acid position was not available. 
Accordingly, it was suggested that this mutation may not be a significant mutation that would 





Table 2.2 Mutation Table 





hnNOSoxyCaM 2242 G → T Gly → Trp 726 
heNOSoxyCaM 1606 – 1608 deletion of ATG Met → Ala 514 
hnNOS 1813 G → C Glu → Gln 583 
2242 G → T Gly → Trp 726 
1567 G → A Gly → Arg 1355 
 
In hnNOS, a guanine was mutated to a cytosine at DNA position 1813. This changed a 
glutamate to a glutamine at amino acid position 583. It was a mutation from a negatively 
charged to a neutral amino acid. Crystal structure of human nNOS oxygenase domain (PDB 
4D1N) showed that the amino acid position is within a β-sheet and is distant from the binding 
sites (Figure 2.10 (b)). An nNOS form that could be related to this mutation was nNOS2 which 
is a splice variant of nNOS. nNOS2 having a deletion of residues 509 – 613 showed to have no 
nNOS activity but an opposing pharmacological role to wild-type nNOS (Iwasaki et al., 1999; 
Kolesnikov et al., 1997). This suggested that our mutant may exhibit features similar to those 
in nNOS2. 
A common mutation was seen in both hnNOSoxyCaM and hnNOS at DNA position 
2242. This made sense since construction of phnNOSoxyCaM involved introduction of a stop 
codon in phnNOS. This mutation changed the codon for glycine to a codon for tryptophan at 
amino acid position 726. This amino acid position was within none of the binding sites. Also, 
no structural data related to the mutation could be found. 
The third mutation that was seen in hnNOS was a mutation from a guanine to an 
adenine at DNA position 1567. In terms of amino acids, it was a mutation from glycine to 
arginine at amino acid position 1355. This position was located to be within the NADPH-
binding region in the reductase domain. The position was further examined in the crystal 
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structure of rat nNOS reductase domain (PDB 1TLL) since crystal structure of human form 
was not available. G1355 in hnNOS was identified to be equivalent to G1350 in the crystal 
structure of rat nNOS. Crystal structure revealed that the amino acid position is between the 
NADPH- and FAD-binding regions and is in the region that is responsible for hydride transfer 
from NADPH to FAD (Figure 2.10 (c)) (Garcin et al., 2004). Also, being a mutation from a 
small hydrophobic residue to a larger positively charged residue, it suggested that the mutation 
may interfere with NOS activity and may be necessary to revert it.   
 
  
Figure 2.10 (a) NOS structures indicating mutation sites in heNOSoxyCaM (top) and 
hnNOS (bottom) (b) Crystal structure of human nNOS oxygenase domain (PDB 4D1N) 
showing E583 and cofactor binding sites (c) Crystal structure of rat nNOS reductase 
domain (PDB 1TLL) showing G1350 with NADPH- and FAD-binding sites (a) is showing 
the mutation sites that occurred in heNOSoxyCaM and hnNOS by PCR amplification of the 
inserts. In (b), cofactor binding sites in the oxygenase domain are shown with E583, which is 
not in close proximity to the binding sites. During the molecular cloning of phnNOS, E583 was 
mutated to a glutamine. (c) showed that G1350, equivalent to G1355 in hnNOS, is present 
between the NADPH- and FAD-binding sites. In phnNOS, G1355 was unintentionally mutated 
to an arginine.  
M514A 






Investigation of Expression and Purification of Human NOS 
Oxygenase Domains 
3.1 Introduction 
 The oxygenase domain is the catalytic domain in NOS that contains the active site. It 
holds the binding sites for a heme, BH4, and L-arginine, and carries out the conversion of L-
arginine into L-citrulline and NO. Previous studies have demonstrated that rat nNOS 
oxygenase domain expressed in E. coli was able to form binding sites as in the holoenzyme 
(McMillan & Masters, 1995). As well, in another study by Rafferty et al., 1999, a mouse iNOS 
oxygenase domain was expressed and purified by a simpler procedure. The study also showed 
that the domain forms a stable dimer. For these reasons, expression and purification of the 
oxygenase domains were first performed.  
 Expressions of human nNOS and eNOS oxygenase domains without the CaM-binding 
regions that are in pDS-78 were attempted at different temperatures for investigation of optimal 
expression temperatures. Then, small-scale purifications of the domains were carried out using 
nickel affinity columns. Human Δ70 iNOS oxygenase domain without the CaM-binding region 
that is in a pCWori vector was expressed and purified as previously described (Spratt, 2008). 
Lastly, human nNOS oxygenase domain with the CaM-binding region in pDS-78 was 
expressed. Purification of hnNOSoxyCaM was done using a nickel affinity column and then 
with a glutathione column. Since a CaM-binding region is present in hnNOSoxyCaM, GST-
TEV-CaM was added to hnNOSoxyCaM obtained from nickel affinity purification. One then 
applied the protein mixture to the glutathione column in which the GST portion would bind to 
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the glutathione column and CaM portion would bind hnNOSoxyCaM for its further 
purification. 
3.2 Methods 
3.2.1 Expression of hnNOSox and heNOSox using pET-based vector 
Initially, E. coli BL21 (DE3) was transformed with phnNOSox for expression of 
hnNOSox. For heNOSox, E. coli BL21 (DE3) transformation was performed with pheNOSox. 
Then, one inoculated a 2-mL Terrific Broth (TB) media containing kanamycin with a colony of 
transformants of phnNOSox or pheNOSox, and allowed cell growth at 37 ˚C, 225 rpm 
overnight. Then, 0.3 mL of the overnight cell culture was added to 30 mL of TB media 
containing kanamycin and it was incubated at 37 ˚C, 225 rpm. When the optical density at 600 
nm reached 0.5, protein expression was induced by adding Isopropyl β-D-1-
thiogalactopyranoside (IPTG, 500 μM). Protein induction occurred for 18 – 24 hours at three 
different temperatures, which were 20 ˚C, 25 ˚C, and 37 ˚C. After protein induction, the cell 
culture was centrifuged at 6 000 rpm for 5 minutes. His binding buffer (20 mM sodium 
phosphate, 500 mM NaCl, 20 mM imidazole, pH 7.4) was used for cell resuspension. Then, 0.2 
mg/mL lysozyme, 1 mM MgCl2, 1 mM PMSF, 3.5 μg/mL E64, 2 μg/mL aprotinin, 0.6 μg/mL 
pepstatin, and 4 μg/mL leupeptin were added and the samples were incubated on ice for 30 
minutes. Cells were lysed by sonication and the cell lysate was centrifuged at 13 000 rpm, 4 ˚C 
for 10 minutes. 
3.2.2 Purification of hnNOSox and heNOSox 
Because of the small sample size, His SpinTrap™ column (GE Healthcare) was used 
and the purification carried out as instructed by the manufacturer. The column was first 
equilibrated with 600 μL of binding buffer, and the eluate was collected by centrifugation at 
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100 x g for 30 s, which was done at the end of every purification step to collect the eluate. 
Supernatant samples were applied, and the column was washed with 600 μL of His binding 
buffer. The protein was eluted twice with 200 μL of His elution buffer (20 mM sodium 
phosphate, 500 mM NaCl, 500 mM imidazole, pH 7.4). 
3.2.3 hiNOSox Expression using pCWori-based vector 
 At first, E. coli BL21 (DE3) cells were electroporated with pCWori-hiNOSox for 
bacterial transformation and were plated on solid Luria-Bertani (LB) broth containing 
ampicillin. Then, an isolated colony was selected for inoculation of 20 mL of TB media 
containing ampicillin. The cell culture was incubated at 37 ˚C, 225 rpm overnight and 5 mL of 
the overnight cell culture was added to 500 mL of TB media. The 500-mL cell culture was 
cultured at 37 ˚C, 225 rpm until it reached an optical density at 600 nm of 1.0. For protein 
induction, IPTG (500 μM), trace metals ((9.6 mg/L FeSO4•7H2O, 2.4 mg/L MnSO4•H2O, 2.4 
mg/L AlCl3•6H2O, 1.0 mg/L CoCl2•6H2O, 0.5 mg/L ZnSO4•7H2O, 2.4 mg/L Na2MoO4•2H2O, 
0.1 mg/L CuCl2•2H2O, and 0.5 mg/L H3BO3), δ-aminolevulinic acid (δ-ALA, 400 μM), and 15 
μL of 45 mg/mL chloramphenicol were added to the cell culture which was then incubated at 
20 ˚C, 225 rpm for 40 hours. Cells were collected by centrifugation, and were resuspended in 
lysis buffer (40 mM TrisHCl, pH 7.5, 10% glycerol, 150 mM NaCl, 10 μM H4B, 3 mM 
ascorbic acid, 1 mM PMSF, 3.5 μg/mL E64, 2 μg/mL aprotinin, 0.6 μg/mL pepstatin, and 4 
μg/mL leupeptin). Cell lysis was done by homogenization and the lysate was centrifuged at 20 
000 rpm, 4 ˚C for 30 minutes. 
3.2.4 hiNOSox Purification 
 To the sample supernatant, ammonium sulfate was added to a final concentration of 35% 
and the sample was stirred at 4 ˚C for 45 minutes. Afterwards, the sample was centrifuged at 
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20 000 rpm, 4 ˚C for 30 minutes, and the supernatant was collected. Ammonium sulfate was 
added to the supernatant to a final concentration of 55%. Again, the sample with ammonium 
sulfate was stirred for 45 minutes at 4 ˚C, and then spun at 20 000 rpm, 4 ˚C for 30 minutes. 
The supernatant was decanted and the pellet was resuspended in ~15 mL of pellet buffer (40 
mM TrisHCl, pH 7.5, 10% glycerol, and 250 mM NaCl).  
 For hiNOSox purification, Ni
2+
-chelating resin with a column volume of 10 mL was 
equilibrated with 5 column volumes of pellet buffer and the 15 mL of pellet sample was 
applied to the column. The column was washed with 10 column volumes of pellet buffer and 
the protein was eluted with 3 column volumes of pellet buffer containing 200 mM imidazole 
and collected as in 2-mL fractions. Then, elution fractions with heme absorbance peaks 
between 700 nm and 300 nm were pooled. The pooled samples were transferred to a dialysis 
bag with a MWCO 6 000 – 8 000. This dialysis bag was placed in 1 L of Dialysis buffer 1 (50 
mM TrisHCl, pH 7.5, 10% glycerol, 250 mM NaCl, 1 mM DTT, 4 μM H4B, 3 mM ascorbic 
acid) overnight at 4 ˚C. Then, the sample was dialysed in 1 L of Dialysis buffer 1 containing 
100 mM NaCl at 4 ˚C overnight. The heme absorbance peak of the final sample was monitored 
between 700 nm and 300 nm.  
3.2.5 hnNOSoxyCaM Expression and Purification 
 For expression of hnNOSoxyCaM, transformation of E. coli BL21 (DE3) was 
performed with the phnNOSoxyCaM plasmid. 20 mL of LB media containing kanamycin was 
inoculated with a colony of the transformants and incubated at 37 ˚C, 225 rpm overnight. 10 
mL of the overnight starter culture was then used for inoculation of 1 L of TB media 
containing kanamycin. The cell culture was grown at 37 ˚C, 225 rpm until an optical density at 
600 nm of 1.1 was reached. Protein expression was induced by addition of IPTG (500 μM), 
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and with it, δ-ALA (400 μM), a heme precursor, and trace metals were also added. Induction 
conditions were 20 ˚C, 225 rpm and protein expression was allowed for 40 hours. A 30 mL 
sample of cell culture was centrifuged at 6 000 rpm for 5 minutes. The rest of the cells were 
harvested by centrifugation at 6 000 rpm for 10 minutes and the cell pellets were then flash 
frozen on dry ice and stored at -80 ˚C.  
 The first step for purification of hnNOSoxyCaM involved the use of His SpinTrap™ 
column (GE Healthcare). The protocol described by the manufacturer was followed with 
several modifications. Initially, the cell pellet from 30 mL of cell culture was resuspended in 
His binding buffer (20 mM sodium phosphate, 500 mM NaCl, 20 mM imidazole, pH 7.4), and 
lysozyme (0.2 mg/mL), MgCl2 (1 mM), and PMSF (1 mM) were added to the cell sample. It 
was left on ice for 30 minutes and then sonicated. The sample was then centrifuged at 13 000 
rpm for 10 minutes at 4 ˚C. The column was first equilibrated with His binding buffer and then 
centrifuged at 100 x g for 30 seconds. Afterwards, the cell supernatant was applied to column 
which was then followed by centrifugation in a similar manner. Since the maximum volume 
the column can hold was 600 μL, sample application was repeated several times. The column 
was washed with 600 μL of His binding buffer and centrifuged. Lastly, protein was eluted by 
centrifugation using 200 μL of His elution buffer (20 mM sodium phosphate, 500 mM NaCl, 
500 mM imidazole, pH 7.4). Addition of 200 μL of His elution buffer was repeated once more 
for a thorough elution of the protein.  
 As a second step for protein purification, purification of hnNOSoxyCaM, that was 
eluted from His SpinTrap™ column, was attempted with GST SpinTrap™ column (GE 
Healthcare) and GST-TEV-CaM. Purification was performed as described by the manufacturer 
along with a few modifications. GST-TEV-CaM was added to hnNOSoxyCaM sample so that 
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hnNOSoxyCaM-to-GST-TEV-CaM ratio would be 1:1. Also, CaCl2 (5 mM) was added to the 
protein sample. GST SpinTrap™ column was prepared similarly to His SpinTrap™ column. 
The column was equilibrated with 600 μL of GST binding buffer (10 mM Na2HPO4, 140 mM 
NaCl, 2.7 mM KCl, 1.8 mM KH2PO4, pH 7.4) and then centrifuged at 100 x g for 30 seconds. 
For each sample application, one added the sample to the column and incubated on ice for 5 
minutes in order to allow optimal protein binding to the resin. Next, 200 μL of GST elution 
buffer (50 mM TrisHCl, 20 mM glutathione, pH 8.0) was added and centrifuged for protein 
elution. The last elution step was repeated once more.  
3.3 Results 
3.3.1 hnNOSox and heNOSox Expression at Different Temperatures 
 Upon expression and purification of hnNOSox and heNOSox, results showed that one 
can obtain the proteins in higher yields at lower expression temperatures. At expression 
temperature of 37 ˚C, hnNOSox (amino acids 1 – 724), whose molecular weight is 83 kDa, 
appeared to not have expressed, as one could not observe a protein band around 83 kDa in the 
elution lanes (Figure 3.1., (a), lanes 7 – 8 ). The elution lanes are similar to the control which 
was obtained with pDS-78 (Figure 3.1, (d), lanes 8 – 9). In contrast, a protein band with the 
expected molecular weight was seen for hnNOSox that was expressed at 25 ˚C (Figure 3.1, (b), 
indicated in red box). The band for hnNOSox seemed to intensify at a lower expression 
temperature of 20 ˚C (Figure 3.1, (c), indicated in a red box). The cell sample with the vector, 
pDS-78, that went through the same purification steps as hnNOSox did not produce such 
protein band, suggesting that hnNOSox expression occurred at 25 ˚C and at 20 ˚C in Figure 3.1 









Figure 3.1 7.5% SDS-PAGEs of hnNOSox purifications with expression temperatures at 
37 ˚C (a), 25 ˚C (b), and 20 ˚C (c) and of same treatment of cell sample with pDS-78 
(control) and expression temperature at 20 ˚C (d). Cell samples that were subjected to 
different expression temperatures were applied to nickel affinity columns for hnNOSox 
purification. Cell sample with pDS-78 which was solely the vector without the hnNOSox insert 
was treated in the same manner as in hnNOSox purification for comparison. For (a), Lane 1 – 
cell lysate; Lane 2 – cell lysate pellet; Lane 3 – cell lysate supernatant; Lanes 4 – 5 – 
flowthrough; Lane 6 – wash; Lanes 7 – 8 – elutions 1 & 2. For (b), (c), and (d), Lane 1 – cell 
lysate; Lane 2 – cell lysate pellet; Lane 3 – cell lysate supernatant; Lanes 4 – 6 – flowthrough; 
Lane 7 – wash; Lanes 8 – 9 – elutions 1 & 2. 
 Similar results to hnNOSox were seen with expression and purification of heNOSox 
(amino acids 1 – 490). heNOSox with a molecular weight of 58 kDa could not be seen at 

















































to be similar to those of the control. While it was hard to analyze the results at an expression 
temperature of 25 ˚C, heNOSox appeared to be visible in the results from expression 
temperature at 20 ˚C (Figure 3.2, (c), indicated in a red box). Such intense protein band of 58 





Figure 3.2 7.5% SDS-PAGEs of heNOSox purifications with expression temperatures at 
37 ˚C (a), 25 ˚C (b), and 20 ˚C (c) and of same treatment of cell sample with pDS-78 
(control) and expression temperature at 20 ˚C (d). Cell samples of heNOSox and pDS-78 
were purified in the same manner as with hnNOSox (Figure 3.1). For (a), Lane 1 – cell lysate; 
Lane 2 – cell lysate pellet; Lane 3 – cell lysate supernatant; Lanes 4 – 5 – flowthrough; Lane 6 
– wash; Lanes 7 – 8 – elutions 1 & 2. For (b), (c), and (d), Lane 1 – cell lysate; Lane 2 – cell 
lysate pellet; Lane 3 – cell lysate supernatant; Lanes 4 – 6 – flowthrough; Lane 7 – wash; 

















































3.3.2 hiNOSox Expression and Purification 
Purification results for hiNOSox (amino acids 71 – 508) at different expression 
temperatures are shown in Figure 3.3. hiNOSox, a protein with a molecular weight of 51 kDa, 
appeared to have expressed as one could identify protein bands with the right size in the elution 
lanes (lanes 14 - 16). However, lane 14 which appeared to have larger amount of hiNOSox 
showed to contain other contaminating protein, while lanes 15 – 16 showed a clean protein 
sample of hiNOSox. The fraction in lane 14 was pooled for dialysis as the highest heme 
absorbance peak was observed with the fraction (results not shown). Subsequently, similar 
protein pattern was seen in the dialysis supernatant (lane 17). Heme absorbance peaks for 
fractions in lane 15 and 16 were also monitored. However, their heme absorbances were lower 
than that of lane 14.   
 
 
Figure 3.3 7.5% SDS-PAGE of hiNOSox purification. 
Purification of hiNOSox involved precipitation by addition of ammonium sulfate and 
purification with a nickel affinity column. Lane 1 – cell lysate before protein induction; Lane 2 
– cell lysate after 40 hours of induction; Lane 3 – cell lysate supernatant; Lane 4 – supernatant 
after 35% (NH4)2SO4 precipitation; Lane 5 – supernatant after 55% (NH4)2SO4 precipitation; 
Lane 6 – resuspended pellet after 55% (NH4)2SO4 precipitation; Lane 7 – flowthrough eluted 
from nickel affinity column; Lane 8 – wash; Lanes 9 – 16 – elutions 1 – 8; Lane 17 – 
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3.3.3 hnNOSoxyCaM Expression and Purification  
In the results from purification of hnNOSoxyCaM (amino acids 1 – 755) with a nickel 
affinity column, hnNOSoxyCaM could be seen in the elution lanes whose molecular weight is 
84 kDa (Figure 3.3, (a), lanes 7 – 8, indicated in red box). However, one also observed an 
intense unknown protein band of approximately 30 kDa in the elution lanes that seems to be 
present in large amounts. Upon purification with a glutathione column, protein bands for 
hnNOSoxyCaM (84 kDa) and GST-TEV-CaM (44 kDa) were hardly seen in the elution lanes 
(Figure 3.3, (b), lanes 4 – 5). GST-TEV-CaM was added in order to obtain a purer sample of 
hnNOSoxyCaM, as GST-TEV-CaM is able to bind to both the glutathione column and CaM-
binding region in hnNOSoxyCaM. The unknown protein of 30 kDa was again found in the 
elution fractions from the glutathione column.  
  
Figure 3.4 7.5% SDS-PAGE results for hnNOSoxyCaM purifications with nickel affinity 
column (a) and subsequent glutathione column (b).  Initially, hnNOSoxyCaM was purified 
with a nickel affinity column and then, GST-TEV-CaM was added to the elution sample which 
was applied to a glutathione column.  (a) Lane 1 – cell lysate; Lane 2 – cell lysate pellet; Lane 
3 – cell lysate supernatant; Lanes 4 – 5 – flowthroughs 1 & 2; Lane 6 – wash; Lanes 7 – 8 – 
elutions 1 & 2. (b) Lane 1 – elution sample from nickel affinity column with added GST-TEV-

































 hnNOSox and heNOSox expression at different temperatures, 20˚C, 25 ˚C, and 37 ˚C 
demonstrated that protein expression occurred best at 20 ˚C. This made sense since activities of 
some proteases are known to reduce at low temperatures which would increase the resulting 
amounts of proteins (Sahdev et al., 2008). As well, it was shown with protein purification that 
the proteins can be purified by nickel affinity columns. However, other contaminating proteins 
seemed to be present as well in the elution fractions. Protein purification may be improved by 
protein precipitation with ammonium sulfate.  
Expression and purification of hiNOSox was moderately successful. One was able to 
acquire pure elution fractions of hiNOSox (Figre 3.2, lanes 15 – 16), although the amounts and 
the heme absorbance peaks were low. However, an elution fraction with a high heme 
absorbance peak (Figure 3.2, lane 14) was obtained. This indicated that the heme was present 
in the active site as in the native enzyme, and with a purer protein sample, spectroscopic 
studies of inhibitor binding may be carried out (Montgomery et al., 2010). Alternatively, 
expression and purification of hiNOSoxyCaM may be attempted which may be further purified 
by a glutathione column with GST-TEV-CaM. 
In the experiment with hnNOSoxyCaM, expression and purification showed that the 
purification procedure needs improvement. hnNOSoxyCaM could be purified by nickel affinity 
purification. However, it was hard to observe purification with glutathione column. This might 
have occurred because of the small sample volume of lysate used or due to the presence of the 
unknown 30-kDa protein in large amounts that might have interfered with hnNOSoxyCaM 
binding. In the future, a large-scale protein purification as well as ammonium sulfate 




Preparation of GST-TEV-CaM and Optimization of Its Cleavage 
Reaction by TEV Protease 
4.1 Introduction 
Glutathione S-transferase-tagged calmodulin or GST-TEV-CaM is a fusion protein of 
glutathione-S-transferase and CaM. Glutathione S-transferase is a protein that can strongly 
bind to glutathione. Due to its strong affinity, it is developed as an affinity tag for protein 
purification (Harper & Speicher, 2011). CaM is a calcium-binding protein which, upon calcium 
binding, undergoes a conformational change and can bind other proteins such as NOS. As such, 
GST-TEV-CaM with two affinity motifs was made which could be used in NOS purification. 
The CaM domain would be able to bind to the CaM-binding region of NOS, while GST can 
bind to glutathione resins and this would allow an alternate method for purifying NOS. The 
third feature in GST-TEV-CaM is the TEV protease cleavage site, ENLYFQG, that is present 
between the CaM and GST domains (Nallamsetty et al., 2004). This site would allow removal 
of the GST domain in sample of NOS and CaM in solution or during column purification.  
In this study, GST-TEV-CaM would be useful in purification of various forms of 
human NOS isozymes. It may be coexpressed with hiNOS and hiNOSoxyCaM since active 
forms are only produced upon coexpression with CaM. GST-TEV-CaM can be used in 
purification of human NOS forms with CaM-binding regions, such hnNOSoxyCaM and 
heNOS. In this chapter, expression and purification of GST-TEV-CaM were performed, and 





4.2.1 Expression and Purification of GST-TEV-CaM 
For expression of GST-TEV-CaM, E. coli BL21 (DE3) was transformed with pGST-
TEV-CaM. Then, a single colony of the transformants was used for inoculation in 20 mL of 
Super Broth (SB) media containing ampicillin. It was incubated for growth at 37 ˚C, 225 rpm 
overnight. 1 L of SB media containing ampicillin was inoculated with 10 mL of overnight cell 
culture, and cells were grown at 37 ˚C, 225 rpm. When an optical density at 600 nm of ~0.8 
was reached, IPTG (500 μM) was added for GST-TEV-CaM expression. Protein was 
expressed at 37 ˚C, 225 rpm for 4 hours, and cells were harvested by centrifugation. 
Afterwards, cells were resuspended in GST binding buffer (10 mM Na2HPO4, 140 mM NaCl, 
2.7 mM KCl, 1.8 mM KH2PO4, pH 7.4) and homogenized for cell lysis. The sample was then 
centrifuged at 20 000 rpm at 4 ˚C for 30 minutes.  
 For GST-TEV-CaM purification, β-mercaptoethanol was added to supernatant sample 
and to the buffers for final concentration of 10 mM. Then, the supernatant sample was applied 
to GSTrap FF column (GE Healthcare) that has been equilibrated with GST binding buffer. 
The purification was carried out at a flow rate of 0.3 mL/min for optimal protein binding. After 
sample application, the column was washed with 5 column volumes of binding buffer, and 
GST-TEV-CaM was eluted off with 10 column volumes of GST elution buffer (50 mM Tris-
HCl, 10 mM reduced glutathione, pH 8.0) in 1-mL fractions.  
4.2.2 Cleavage Reaction of GST-TEV-CaM by TEV Protease  
The reaction buffer consisted of 50 mM TrisHCl, pH 8.0, 0.5 mM EDTA, and 1 mM 
DTT. For optimization of reaction conditions, protease-to-substrate ratio, temperature, and 
reaction duration were varied. Protease-to-substrate ratios tested were 1:100, 1:50, and 1:10. 
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These ratios were based on sample absorbances at 280 nm. TEV protease reactions were 
attempted at room temperature and 4 ˚C for 30 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 
and overnight.  
4.3 Results 
4.3.1 GST-TEV-CaM Expression and Purification 
 SDS-PAGE results of GST-TEV-CaM preparation revealed that production of GST-
TEV-CaM of 44kDa, occurred well. Large amount of it was seen in the flowthrough (Figure 
4.1, lanes 1 – 5). Also, small amount of it was observed in the wash fractions (Figure 4.1, lanes 
6 – 11). Lastly, one could notice that large amount of it was eluted in one fraction during 
elution (Figure 4.1, lane 12).  
  
Figure 4.1 15% SDS-PAGE of GST-TEV-CaM purification with glutathione column. This 
figure shows the SDS-PAGE results of protein samples eluted in various stages of GST-TEV-
CaM purification. Lanes 1 – 5 – flowthroughs; Lanes 6 – 11 – wash; Lanes 12 – 17 – elutions. 
  
























4.3.2 TEV reactions of GST-TEV-CaM in Different Reaction Conditions 
In Figure 4.2, protein band around 45-kDa ladder represented GST-TEV-CaM whose 
molecular weight is 44 kDa. TEV protease and cleaved GST appeared as one protein band as 
they have similar molecular weights. The molecular weight of TEV protease is 27 kDa, while 
that of GST is 26 kDa. The smallest protein that ran down the furthest was CaM which has a 
molecular weight of 17 kDa. Sufficient cleavages of GST-TEV-CaM were mostly seen in TEV 
reactions at ratio of 1:10 for both temperatures. In particular, TEV reactions at ratio of 1:10 at 
room temperature showed to have little amounts of GST-TEV-CaM left. TEV reactions at ratio 
of 1:10 at 4 ˚C also demonstrated high cleavage activity but not as much as those at room 









Figure 4.2 15% SDS-PAGE of TEV protease reactions of GST-TEV-CaM at room 
temperature (a) and at 4 ˚C (b). Cleavage reactions of GST-TEV-CaM by TEV protease 
were performed at room temperature and at 4 ˚C with varying protease-to-substrate ratios and 
durations. Lanes 1 – 3 ran undigested GST-TEV-CaM, TEV protease, and CaM, respectively, 
as controls. Lanes 4 – 8 contained reactions with protease-to-substrate ratio of 1:100, while 
lanes 9 – 12 had those of 1:50 and lanes 13 – 18 had those of 1:10. For each ratio, reaction with 
the shortest time was added first and the one with the next shortest time was added to the next 
right lane. Time durations tested were 30 minutes 1 hour, 1 hour 30 minutes, 2 hours, and 






















































 From the results for GST-TEV-CaM expression and purification, it was shown that 
GST-TEV-CaM could be expressed and purified by a glutathione column in large amounts. 
Digestion results showed that reaction condition with protease-to-substrate ratio of 1:10 can 
achieve cleavage of most GST-TEV-CaM in the sample. Reaction condition at ratio of 1:10 
and 4 ˚C for 2 hours seemed to be favourable for cleavage of GST-TEV-CaM in the presence 
of NOS. This is because TEV protease is a highly reactive protease which might also degrade 
NOS in an overnight reaction. Reaction conditions at ratio of 1:10 at room temperature 
appeared to be good but not in the presence of unstable proteins such as NOS. 
Our result agreed well to studies done by Fang et al. (2007). Their results demonstrated 
that with increasing concentration of TEV protease at 30 ˚C, the cleavage reaction reached a 
plateau approximately at protease-to-substrate ratio of 1:20. Similar results could be seen in 
our results where the cleavage reaction at protease-to-substrate ratio of 1:10 was most efficient 
compared to those at 1:100 and 1:50 at both temperatures. In regards to reaction time, studies 
by Fang et al. (2007) presented that although longer reaction time resulted in more protein 
cleavage at 30 ˚C at ratio of 1:10, most of the cleavage reaction occurred in the first several 
hours. Similarly in our results, almost all GST-TEV-CaM was observed to be cleaved in the 
overnight reaction but reaction time of 2 hours also seemed to be enough for cleavage of most 
of GST-TEV-CaM.  
With TEV protease reactions at two different temperatures, room temperature and 4 ˚C, 
results showed that although the protease was more active at room temperatures, it was still 
able to cleave at 4 ˚C. This corresponded well to published results by Nallamsetty et al. (2004). 
This study demonstrated that optimal temperature for TEV protease activity was 30 ˚C while 
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its activity decreased at low temperatures. These reaction conditions would allow cleavage 
reaction by TEV protease of GST-TEV-CaM in purification of NOS which is an unstable 






 Future work with the expression systems described in Chapter 1 will include production 
of human forms of NOS isozymes and various oxygenase domains. As a next step for 
hnNOSoxyCaM purification in Chapter 2, a large-scale expression and purification of 
hnNOSoxyCaM with GST-TEV-CaM may be performed. Ammonium sulfate precipitation of 
hnNOSoxyCaM will need to be carried out prior to column application for removal of 
contaminating proteins which may interfere with hnNOSoxyCaM purification. Larger nickel 
affinity and glutathione columns with greater binding capacities could be used for purification 
of hnNOSoxyCaM in larger amounts. In a similar manner, expression and purification of 
heNOSoxyCaM can be attempted. For production of hiNOS, the protein will need to be 
coexpressed with GST-TEV-CaM, as iNOS expression was found to only work upon 
coexpression with CaM (Spratt, 2008). The cell lysate from coexpression of hiNOS and GST-
TEV-CaM then could be directly applied to glutathione column without further addition of 
GST-TEV-CaM. 
 Once a NOS holoenzyme or oxygenase domain has been purified in large scale, the 
heme in the active site can be analyzed by ultraviolet-visible spectroscopy from which 
information on the state of the heme iron can be obtained. Upon addition of NOS inhibitors, 
the change in spectrum for the heme iron can be monitored and binding of inhibitors in the 
active site can be examined (Montgomery et al., 2010).  
 NOS Inhibitor binding may also be studied by generation of NOS biosensors, similarly 
to cytochrome P450 biosensors that are currently being developed. The purified NOSoxyCaM 
protein may be immobilized to an electrode with the CaM-binding region and NOS oxygenase 
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activity may be assayed by electron transfer from the electrode to the enzyme in the absence 
and presence of various NOS inhibitors (Schneider & Clark, 2013).   
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Appendix –Sequences and Sequence Analysis of Various Forms of 
Human NOS Isozymes 
 
phnNOSox – human nNOS oxidase domain without calmodulin-binding region in pDS-78 


















hnNOSox (cont’d – 3) 
 
 
Sequencing summary of hnNOSox – sequencing complete 
 
DNA section DNA sequencing Primer to be used 
1 – 2248 Complete – 
 



































Blast results of hnNOSox 
 
Score Expect Method Identities Positives Gaps Frame 
1518 bits(3931) 0.0 Compositional matrix adjust. 724/724(100%) 724/724(100%) 0/724(0%) +1 
Query  67    MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA  246 
             MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA 
Sbjct  1     MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA  60 
 
Query  247   GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI  426 
             GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI 
Sbjct  61    GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI  120 
 
Query  427   RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP  606 
             RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP 
Sbjct  121   RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP  180 
 
Query  607   RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV  786 
             RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV 
Sbjct  181   RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV  240 
 
Query  787   DRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPS  966 
             DRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPS 
Sbjct  241   DRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPS  300 
 
Query  967   KCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLF  1146 
             KCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLF 
Sbjct  301   KCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLF  360 
 
Query  1147  PLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC  1326 
             PLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC 
Sbjct  361   PLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC  420 
 
Query  1327  VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW  1506 
             VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW 
Sbjct  421   VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW  480 
 
Query  1507  NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQ  1686 
             NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQ 
59 
 
Sbjct  481   NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQ  540 
 
Query  1687  IPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGV  1866 
             IPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGV 
Sbjct  541   IPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGV  600 
 
Query  1867  RDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSAT  2046 
             RDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSAT 
Sbjct  601   RDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSAT  660 
 
Query  2047  ESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHV  2226 
             ESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHV 
Sbjct  661   ESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHV  720 
 
Query  2227  WKGT  2238 
             WKGT 




















heNOSox (cont’d – 2) 
 
 
Sequencing summary of heNOSox – sequencing complete 
 
DNA section DNA sequencing Primer to be used 
1 – 1567 Complete – 
 




























Blast results of heNOSox 
 
Score Expect Method Identities Positives Gaps Frame 
847 bits(2188) 0.0 Compositional matrix adjust. 489/489(100%) 489/489(100%) 0/489(0%) +1 
Query  91    GNLKSVAQEpgppcglglglglglcgKQGpatpapepsrapasllppapehsppssplTQ  270 
             GNLKSVAQEPGPPCGLGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAPEHSPPSSPLTQ 
Sbjct  2     GNLKSVAQEPGPPCGLGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAPEHSPPSSPLTQ  61 
 
Query  271   PPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPE  450 
             PPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPE 
Sbjct  62    PPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPE  121 
 
Query  451   QLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNA  630 
             QLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNA 
Sbjct  122   QLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNA  181 
 
Query  631   PRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDF  810 
             PRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDF 
Sbjct  182   PRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDF  241 
 
Query  811   RIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQApdeppe  990 
             RIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPPE 
Sbjct  242   RIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPPE  301 
 
Query  991   lfllppelvlevplehptleWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTE  1170 
             LFLLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTE 
Sbjct  302   LFLLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTE  361 
 
Query  1171  IGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHH  1350 
             IGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHH 
Sbjct  362   IGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHH  421 
 
Query  1351  AATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWK  1530 
             AATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWK 
Sbjct  422   AATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWK  481 
 
Query  1531  GSAAKGTGI  1557 
             GSAAKGTGI 
65 
 
Sbjct  482   GSAAKGTGI  490 
 
Lower case grey letters represent low-complexity sequences. It is an automatic filter in BLAST to indicate that a match is likely an 
artifact when a user is searching for sequence homology.  
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hiNOSox (cont’d – 2) 
 
 
Sequencing summary of hiNOSox 
 
DNA section DNA sequencing Primer to be used 
1 – 165  Incomplete pCWOri-fr 
166 – 1176  Complete – 
1177 – 1206  Incomplete 1000iNOSfr 
1207 – 1338  Complete – 
 
















































Score Expect Method Identities Positives Gaps Frame 
728 bits(1879) 0.0 Compositional matrix adjust. 354/379(93%) 360/379(94%) 6/379(1%) +3 
Query  21    GVIMTPKSLTRGPRDKPTPPDELLPQAIEFVNQYYGSFKEAKIEEHLARVEAVTKEIETT  200 
             G IMTPKSLTRGPRDKPTPPDELLPQAIEFVNQYYGSFKEAKIEEHLARVEAVTKEIETT 
Sbjct  117   GSIMTPKSLTRGPRDKPTPPDELLPQAIEFVNQYYGSFKEAKIEEHLARVEAVTKEIETT  176 
 
Query  201   GTYQLTGDELIFATKQAWRNAPRCIGRIQWSNLQVFDARSCSTAREMFEHICRHVRYSTN  380 
             GTYQLTGDELIFATKQAWRNAPRCIGRIQWSNLQVFDARSCSTAREMFEHICRHVRYSTN 
Sbjct  177   GTYQLTGDELIFATKQAWRNAPRCIGRIQWSNLQVFDARSCSTAREMFEHICRHVRYSTN  236 
 
Query  381   NGNIRSAITVFPQRSDGKHDFRVWNAQLIRYAGYQMPDGSIRGDPANVEFTQLCIDLGWK  560 
             NGNIRSAITVFPQRSDGKHDFRVWNAQLIRYAGYQMPDGSIRGDPANVEFTQLCIDLGWK 
Sbjct  237   NGNIRSAITVFPQRSDGKHDFRVWNAQLIRYAGYQMPDGSIRGDPANVEFTQLCIDLGWK  296 
 
Query  561   PKYGRFDVVPLVLQANGRDPELFEIPPDLVLEVAMEHPKYEWFRELELKWYALPAVANML  740 
             PKYGRFDVVPLVLQANGRDPELFEIPPDLVLEVAMEHPKYEWFRELELKWYALPAVANML 
Sbjct  297   PKYGRFDVVPLVLQANGRDPELFEIPPDLVLEVAMEHPKYEWFRELELKWYALPAVANML  356 
 
Query  741   LEVGGLEFPGCPFNGWYMGTEIGVRDFCDVQRYNILEEVGRRMGLETHKLASLWKDQAVV  920 
             LEVGGLEFPGCPFNGWYMGTEIGVRDFCDVQRYNILEEVGRRMGLETHKLASLWKDQAVV 
Sbjct  357   LEVGGLEFPGCPFNGWYMGTEIGVRDFCDVQRYNILEEVGRRMGLETHKLASLWKDQAVV  416 
 
Query  921   EINIAVLHSFQKQNVTIMDHHSAAESFMKYMQNEYRSRGGLPGRLEFGWSLPCL-GASPX  1097 
             EINIAVLHSFQKQNVTIMDHHSAAESFMKYMQNEYRSRGG P   ++ W +P + G+    
Sbjct  417   EINIAVLHSFQKQNVTIMDHHSAAESFMKYMQNEYRSRGGCPA--DWIWLVPPMSGSITP  474 
 
Query  1098  VFHRRC*LRPV--PFYYYQ  1148 
             VFH+   L  V  PFYYYQ 







Score Expect Method Identities Positives Gaps Frame 
96.3 bits(238) 2e-25 Compositional matrix adjust. 43/43(100%) 43/43(100%) 0/43(0%) +3 
Query  21   PPMSGSITPVFHQEMLNYVLSPFYYYQVEAWKTHVWQDEKRRP  149 
            PPMSGSITPVFHQEMLNYVLSPFYYYQVEAWKTHVWQDEKRRP 
Sbjct  466  PPMSGSITPVFHQEMLNYVLSPFYYYQVEAWKTHVWQDEKRRP  508 
72 
 









Sequence details of hnNOSoxyCaM 
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hnNOSoxyCaM (cont’d – 3) 
 
Sequencing summary of hnNOSoxyCaM – sequencing complete 
 
DNA section DNA sequencing Primer to be used 
1 – 2334 Complete – 
 
Mutation found in hnNOSoxyCaM 
 
DNA position Mutation Amino acid change Amino acid position 
2242 G → T Gly → Trp 726 
 















































































Score Expect Method Identities Positives Gaps Frame 
535 bits(1377) 0.0 Compositional matrix adjust. 277/321(86%) 283/321(88%) 5/321(1%) +2 
Query  122   MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA  301 
             MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA 
Sbjct  1     MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA  60 
 
Query  302   GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI  481 
             GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI 
Sbjct  61    GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI  120 
 
Query  482   RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP  661 
             RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP 
Sbjct  121   RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP  180 
 
Query  662   RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV  841 
             RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV 
Sbjct  181   RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV  240 
 
Query  842   DRDLDGKSHKPLPLGVRTTESS*PM-GEGQCACRPQHXYSEKEQPPPQ-KTVPXKNAAP-  1012 
             DRDLDGKSHKPLPLGV        + G+G       + YSEKEQPP   K  P KN +P  
Sbjct  241   DRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPS  300 
 
Query  1013  QC--HASQSDWXTECXLXPPL  1069 
             +C       +W TE  L   L 




Score Expect Method Identities Positives Gaps Frame 
623 bits(1606) 0.0 Compositional matrix adjust. 291/295(99%) 293/295(99%) 0/295(0%) +3 
Query  12   IGIQVDRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTK  191 
            +GIQVDRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTK 
79 
 
Sbjct  236  MGIQVDRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTK  295 
 
Query  192  NGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRT  371 
            NGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRT 
Sbjct  296  NGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRT  355 
 
Query  372  KGQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWR  551 
            KGQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWR 
Sbjct  356  KGQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWR  415 
 
Query  552  NASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKH  731 
            NASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKH 
Sbjct  416  NASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKH  475 
 
Query  732  DFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLCFR  896 
            DFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPL  + 




Score Expect Method Identities Positives Gaps Frame 
512 bits(1319) 0.0 Compositional matrix adjust. 242/256(95%) 243/256(94%) 2/256(0%) +1 
Query  1    PRFXASSXQNWETEVVLTDTLHLKXXLETGCTEYICMGSIXHPSQHARRPEDVRTKGQLF  180 
            PRF     +NWETEVVLTDTLHLK  LETGCTEYICMGSI HPSQHARRPEDVRTKGQLF 
Sbjct  303  PRFL--KVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLF  360 
 
Query  181  PLAKEFIDQYYSSIKRFGSKXHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC  360 
            PLAKEFIDQYYSSIKRFGSK HMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC 
Sbjct  361  PLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC  420 
 
Query  361  VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW  540 
            VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW 
Sbjct  421  VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW  480 
 
Query  541  NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQ  720 
            NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQ 




Query  721  IPPELVLEVPISTPSL  768 
            IPPELVLEVPI  P   




Score Expect Method Identities Positives Gaps Frame 
641 bits(1654) 0.0 Compositional matrix adjust. 307/332(92%) 312/332(93%) 2/332(0%) +3 
Query  6    CITIFPQRTDGKHDFRVWNSQLXRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRF  185 
             ITIFPQRTDGKHDFRVWNSQL RYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRF 
Sbjct  463  AITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRF  522 
 
Query  186  DVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGL  365 
            DVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGL 
Sbjct  523  DVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGL  582 
 
Query  366  EFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAV  545 
            EFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAV 
Sbjct  583  EFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAV  642 
 
Query  546  LYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLN  725 
            LYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLN 
Sbjct  643  LYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLN  702 
 
Query  726  YRLTPSFEYQPDPWNTHVWKGTNWTPTKRRAIGFKKLAEAVKFSAKLMGQAMA*NSKATI  905 
            YRLTPSFEYQPDPWNTHVWKGTN TPTKRRAIGFKKLAEAVKFSAKLMGQAMA   KATI 
Sbjct  703  YRLTPSFEYQPDPWNTHVWKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATI  762 
 
Query  906  LYATETGNRKLMPDLV*DL-QHAL-MPXMSME  995 
            LYATETG  +     + ++ +HA     MSME 
























heNOSoxyCaM (cont’d – 2) 
 
 
Sequencing summary of heNOSoxyCaM – sequencing complete 
 
DNA section DNA sequencing Primer to be used 
1 – 1611 Complete – 
 
Mutation found in heNOSoxyCaM 
 
DNA position Mutation Amino acid change Amino acid position 


































































Score Expect Method Identities Positives Gaps Frame 
424 bits(1090) 4e-141 Compositional matrix adjust. 260/263(99%) 260/263(98%) 0/263(0%) +3 
Query  129  MGNLKSVAQEpgppcglglglglglcgKQGpatpapepsrapasllppapehsppssplT  308 
            MGNLKSVAQEPGPPCGLGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAPEHSPPSSPLT 
Sbjct  1    MGNLKSVAQEPGPPCGLGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAPEHSPPSSPLT  60 
 
Query  309  QPPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAP  488 
            QPPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAP 
Sbjct  61   QPPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAP  120 
 
Query  489  EQLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRN  668 
            EQLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRN 
Sbjct  121  EQLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRN  180 
 
Query  669  APRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGD  848 
            APRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGD 
Sbjct  181  APRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGD  240 
 
Query  849  FXIWNSQLVRYAAYRQQDGSXRG  917 
            F IWNSQLVRYA YRQQDGS RG 




Score Expect Method Identities Positives Gaps Frame 
508 bits(1309) 4e-173 Compositional matrix adjust. 280/326(86%) 291/326(89%) 4/326(1%) +1 
Query  28   GRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWN  207 
            GRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWN 
Sbjct  186  GRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWN  245 
 
Query  208  SQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQApdeppelfll  387 
            SQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPPELFLL 
87 
 
Sbjct  246  SQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPPELFLL  305 
 
Query  388  ppelvlevplehptleWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIGTR  567 
            PPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIGTR 
Sbjct  306  PPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIGTR  365 
 
Query  568  NLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAATA  747 
            NLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAATA 
Sbjct  366  NLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAATA  425 
 
Query  748  SFMKHLQNEQKARGGCPADWAWIVPP-SRAASLLFSIRRWSTISCPRPSATSQTLEGECR  924 
            SFMKHL+NEQKARGGCPADWAWIVPP S + + +F     +    P         +G    
Sbjct  426  SFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWKGSAA  485 
 
Query  925  KGTA-SQEEDFKKCTR--XISASLMA  993 
            KGT  ++++ FK+      ISASLM  




Score Expect Method Identities Positives Gaps Frame 
616 bits(1588) 0.0 Compositional matrix adjust. 308/340(91%) 310/340(91%) 2/340(0%) +3 
Query  45    FSGWYMSTEXXTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQL  224 
             FSGWYMSTE  TRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQL 
Sbjct  353   FSGWYMSTEIGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQL  412 
 
Query  225   AKVTIVDHHAATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPA  404 
             AKVTIVDHHAATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPA 
Sbjct  413   AKVTIVDHHAATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPA  472 
 
Query  405   FRYQPDPWKGSAAKGTGITRKKTFKEVANAVKISASLMGTV-A*ALKATILYGSETGRAQ  581 
             FRYQPDPWKGSAAKGTGITRKKTFKEVANAVKISASLMGTV A  +KATILYGSETGRAQ 
Sbjct  473   FRYQPDPWKGSAAKGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQ  532 
 
Query  582   SYAQQLGRLFRKAFDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALME  761 
             SYAQQLGRLFRKAFDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALME 




Query  762   MSGPYNSSPRPEQHKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGXLXTLRFCVFGL  941 
             MSGPYNSSPRPEQHKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAG L TLRFCVFGL 
Sbjct  593   MSGPYNSSPRPEQHKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGL  652 
 
Query  942   GSGHTPTSAPLLVP*XTAGGTXXGA-LLXLGQGDELCARE  1058 
             GS   P          T      G  LL LGQGDELC +E 











pCWori-hiNOSoxyCaM – human Δ70 iNOS oxygenase domain with calmodulin-binding 








Sequence details of hiNOSoxyCaM 
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hiNOSoxyCaM (cont’d – 2) 
 
 
Sequencing summary of hiNOSoxyCaM 
 
DNA section DNA sequencing Primer to be used 
1 – 165  Incomplete pCWOri-fr 
166 – 1425 Complete – 
 
No mutation was found in the sequencing results of hiNOSoxyCaM. 
 



































Score Expect Method Identities Positives Gaps Frame 
431 bits(1108) 4e-147 Compositional matrix adjust. 203/204(99%) 203/204(99%) 0/204(0%) +3 
Query  21   GVIMTPKSLTRGPRDKPTPPDELLPQAIEFVNQYYGSFKEAKIEEHLARVEAVTKEIETT  200 
            G IMTPKSLTRGPRDKPTPPDELLPQAIEFVNQYYGSFKEAKIEEHLARVEAVTKEIETT 
Sbjct  117  GSIMTPKSLTRGPRDKPTPPDELLPQAIEFVNQYYGSFKEAKIEEHLARVEAVTKEIETT  176 
 
Query  201  GTYQLTGDELIFATKQAWRNAPRCIGRIQWSNLQVFDARSCSTAREMFEHICRHVRYSTN  380 
            GTYQLTGDELIFATKQAWRNAPRCIGRIQWSNLQVFDARSCSTAREMFEHICRHVRYSTN 
Sbjct  177  GTYQLTGDELIFATKQAWRNAPRCIGRIQWSNLQVFDARSCSTAREMFEHICRHVRYSTN  236 
 
Query  381  NGNIRSAITVFPQRSDGKHDFRVWNAQLIRYAGYQMPDGSIRGDPANVEFTQLCIDLGWK  560 
            NGNIRSAITVFPQRSDGKHDFRVWNAQLIRYAGYQMPDGSIRGDPANVEFTQLCIDLGWK 
Sbjct  237  NGNIRSAITVFPQRSDGKHDFRVWNAQLIRYAGYQMPDGSIRGDPANVEFTQLCIDLGWK  296 
 
Query  561  PKYGRFDVVPLVLQANGRDPELFE  632 
            PKYGRFDVVPLVLQANGRDPELFE 




Score Expect Method Identities Positives Gaps Frame 
325 bits(832) 4e-108 Compositional matrix adjust. 151/151(100%) 151/151(100%) 0/151(0%) +1 
Query  1    IPPDLVLEVAMEHPKYEWFRELELKWYALPAVANMLLEVGGLEFPGCPFNGWYMGTEIGV  180 
            IPPDLVLEVAMEHPKYEWFRELELKWYALPAVANMLLEVGGLEFPGCPFNGWYMGTEIGV 
Sbjct  321  IPPDLVLEVAMEHPKYEWFRELELKWYALPAVANMLLEVGGLEFPGCPFNGWYMGTEIGV  380 
 
Query  181  RDFCDVQRYNILEEVGRRMGLETHKLASLWKDQAVVEINIAVLHSFQKQNVTIMDHHSAA  360 
            RDFCDVQRYNILEEVGRRMGLETHKLASLWKDQAVVEINIAVLHSFQKQNVTIMDHHSAA 
Sbjct  381  RDFCDVQRYNILEEVGRRMGLETHKLASLWKDQAVVEINIAVLHSFQKQNVTIMDHHSAA  440 
 
Query  361  ESFMKYMQNEYRSRGGCPADWIWLVPPMSGS  453 
            ESFMKYMQNEYRSRGGCPADWIWLVPPMSGS 
94 
 




Score Expect Method Identities Positives Gaps Frame 
140 bits(354) 7e-44 Compositional matrix adjust. 66/66(100%) 66/66(100%) 0/66(0%) +1 
Query  1    ITPVFHQEMLNYVLSPFYYYQVEAWKTHVWQDEKRRPKRREIPLKVLVKAVLFACMLMRK  180 
            ITPVFHQEMLNYVLSPFYYYQVEAWKTHVWQDEKRRPKRREIPLKVLVKAVLFACMLMRK 
Sbjct  472  ITPVFHQEMLNYVLSPFYYYQVEAWKTHVWQDEKRRPKRREIPLKVLVKAVLFACMLMRK  531 
 
Query  181  TMASRV  198 
            TMASRV 














Sequence details of hnNOS 
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hnNOS (cont’d – 5) 
 
Sequencing summary of hnNOS 
 
DNA section DNA sequencing Primer to be used 
1 – 2391 Complete – 
2392 – 2562  Incomplete hnNOSfr2600 
2563 – 4371 Complete – 
 
Mutations found in hnNOS 
 
DNA position Mutation Amino acid change Amino acid position 
1813 G → C Glu → Gln 583 
2242 G → T Gly → Trp 726 
1567 G → A Gly → Arg 1355 
 



















































































































Score Expect Method Identities Positives Gaps Frame 
579 bits(1493) 0.0 Compositional matrix adjust. 308/352(88%) 316/352(89%) 8/352(2%) +1 
Query  121   MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA  300 
             MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA 
Sbjct  1     MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA  60 
 
Query  301   GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI  480 
             GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI 
Sbjct  61    GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI  120 
 
Query  481   RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP  660 
             RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP 
Sbjct  121   RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP  180 
 
Query  661   RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV  840 
             RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV 
Sbjct  181   RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV  240 
 
Query  841   DRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSekeqpppqensppqRMAAP-  1017 
             DRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPP      P +  +P  
Sbjct  241   DRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPS  300 
 
Query  1018  QC-HASQGQNWETE-CLTDXLHLEHMKRDALSTSAWL--IMH-LXHAELRRP  1158 
             +C    + +NWETE  LTD LHL+       +    +  IMH   HA  RRP 







Score Expect Method Identities Positives Gaps Frame 
58.2 bits(139) 2e-15 Compositional matrix adjust. 27/27(100%) 27/27(100%) 0/27(0%) +1 
Query  1    EKEQPPTSGKQSPTKNGSPSKCPRFLK  81 
            EKEQPPTSGKQSPTKNGSPSKCPRFLK 




Score Expect Method Identities Positives Gaps Frame 
678 bits(1750) 0.0 Compositional matrix adjust. 316/318(99%) 318/318(100%) 0/318(0%) +1 
Query  19   QVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLFPLAKEF  198 
            +VKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLFPLAKEF 
Sbjct  307  KVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLFPLAKEF  366 
 
Query  199  IDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRCVGRIQW  378 
            IDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRCVGRIQW 
Sbjct  367  IDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRCVGRIQW  426 
 
Query  379  SKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIR  558 
            SKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIR 
Sbjct  427  SKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIR  486 
 
Query  559  YAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELV  738 
            YAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELV 
Sbjct  487  YAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELV  546 
 
Query  739  LEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLQFSACPFSGWYMGTEIGVRDYCDN  918 
            LEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGL+FSACPFSGWYMGTEIGVRDYCDN 
Sbjct  547  LEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDN  606 
 
Query  919  SRYNILEEVAKKMNLDMR  972 
            SRYNILEEVAKKMNLDMR 






Score Expect Method Identities Positives Gaps Frame 
669 bits(1727) 0.0 Compositional matrix adjust. 325/350(93%) 326/350(93%) 8/350(2%) +2 
Query  8     CITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRF  187 
              ITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRF 
Sbjct  463   AITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRF  522 
 
Query  188   DVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGL  367 
             DVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGL 
Sbjct  523   DVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGL  582 
 
Query  368   EFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAV  547 
             EFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAV 
Sbjct  583   EFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAV  642 
 
Query  548   LYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLN  727 
             LYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLN 
Sbjct  643   LYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLN  702 
 
Query  728   YRLTPSFEYQPDPWNTHVWKGTNWTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATI  907 
             YRLTPSFEYQPDPWNTHVWKGTN TPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATI 
Sbjct  703   YRLTPSFEYQPDPWNTHVWKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATI  762 
 
Query  908   LYATETGKSQAYARP-CVRSSTRL*CKVMSW-RYDIVHWT*TLVLCHSTL  1051 
             LYATETGKSQAYA+  C         KVMS   YDIVH      L H TL 




Score Expect Method Identities Positives Gaps Frame 
499 bits(1284) 7e-170 Compositional matrix adjust. 240/240(100%) 240/240(100%) 0/240(0%) +1 
Query  1     ELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANNSLISNDRSW  180 
             ELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANNSLISNDRSW 




Query  181   KRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFVRLHTNGSQE  360 
             KRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFVRLHTNGSQE 
Sbjct  970   KRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFVRLHTNGSQE  1029 
 
Query  361   LQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGVISNWTDELR  540 
             LQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGVISNWTDELR 
Sbjct  1030  LQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGVISNWTDELR  1089 
 
Query  541   LPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEYEEWKWGKNP  720 
             LPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEYEEWKWGKNP 




Score Expect Method Identities Positives Gaps Frame 
172 bits(437) 2e-54 Composition-based stats. 92/92(100%) 92/92(100%) 0/92(0%) +1 
Query  1     TIVEVLEEFPSIQMPAtllltqlsllqPRYYSISSSPDMYPDEVHLTVAIVSYRTRDGEG  180 
             TIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIVSYRTRDGEG 
Sbjct  1150  TIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIVSYRTRDGEG  1209 
 
Query  181   PIHHGVCSSWLNRIQADELVPCFVRGAPSFHL  276 
             PIHHGVCSSWLNRIQADELVPCFVRGAPSFHL 




Score Expect Method Identities Positives Gaps Frame 
304 bits(779) 3e-100 Compositional matrix adjust. 144/145(99%) 144/145(99%) 0/145(0%) +1 
Query  1     PRNPQVPCILVGPGTGIAPFRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREET  180 
             PRNPQVPCILVGPGTGIAPFRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREET 
Sbjct  1242  PRNPQVPCILVGPGTGIAPFRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREET  1301 
 
Query  181   LQAKNKGVFRELYTAYSREPDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCRDVTMAA  360 
             LQAKNKGVFRELYTAYSREPDKPKKYVQDILQEQLAESVYRALKEQGGHIYVC DVTMAA 




Query  361   DVLKAIQRIMTQQGKLSAEDAGVFI  435 
             DVLKAIQRIMTQQGKLSAEDAGVFI 




Score Expect Method Identities Positives Gaps Frame 
291 bits(746) 2e-91 Composition-based stats. 141/143(99%) 142/143(99%) 0/143(0%) +3 
Query  18    QIDHIYREETLQAKNKGVFRELYTAYSREPDKPKKYVQDILQEQLAESVYRALKEQGGHI  197 
             +IDHIYREETLQAKNKGVFRELYTAYSREPDKPKKYVQDILQEQLAESVYRALKEQGGHI 
Sbjct  1292  KIDHIYREETLQAKNKGVFRELYTAYSREPDKPKKYVQDILQEQLAESVYRALKEQGGHI  1351 
 
Query  198   YVCRDVTMAADVLKAIQRIMTQQGKLSAEDAGVFISRMRDDNRYHEDIFGVTLRTYEVTN  377 
             YVC DVTMAADVLKAIQRIMTQQGKLSAEDAGVFISRMRDDNRYHEDIFGVTLRTYEVTN 
Sbjct  1352  YVCGDVTMAADVLKAIQRIMTQQGKLSAEDAGVFISRMRDDNRYHEDIFGVTLRTYEVTN  1411 
 
Query  378   RLRSESIAFIEESKKDTDEVFSS  446 
             RLRSESIAFIEESKKDTDEVFSS 
Sbjct  1412  RLRSESIAFIEESKKDTDEVFSS  1434 
108 
 























heNOS (cont’d – 4) 
 Sequencing summary of heNOS 
 
DNA section DNA sequencing Primer to be used 
1 – 1374 Complete – 
1375 – 1524 Incomplete heNOS1280fr 
1525 – 3678  Complete – 
 
No mutation was found in the sequencing results of heNOS. 
 







































































































Blast results of heNOS 
T7 
 
Score Expect Method Identities Positives Gaps Frame 
473 bits(1218) 3e-159 Compositional matrix adjust. 280/280(100%) 280/280(100%) 0/280(0%) +3 
Query  123  MGNLKSVAQEpgppcglglglglglcgKQGpatpapepsrapasllppapehsppssplT  302 
            MGNLKSVAQEPGPPCGLGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAPEHSPPSSPLT 
Sbjct  1    MGNLKSVAQEPGPPCGLGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAPEHSPPSSPLT  60 
 
Query  303  QPPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAP  482 
            QPPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAP 
Sbjct  61   QPPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAP  120 
 
Query  483  EQLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRN  662 
            EQLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRN 
Sbjct  121  EQLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRN  180 
 
Query  663  APRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGD  842 
            APRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGD 
Sbjct  181  APRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGD  240 
 
Query  843  FRIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWT  962 
            FRIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWT 




Score Expect Method Identities Positives Gaps Frame 
476 bits(1224) 6e-163 Compositional matrix adjust. 253/253(100%) 253/253(100%) 0/253(0%) +1 
Query  1    CVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRI  180 
            CVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRI 
Sbjct  184  CVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRI  243 
 
Query  181  WNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQApdeppelf  360 
            WNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPPELF 
116 
 
Sbjct  244  WNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPPELF  303 
 
Query  361  llppelvlevplehptleWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIG  540 
            LLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIG 
Sbjct  304  LLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIG  363 
 
Query  541  TRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAA  720 
            TRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAA 
Sbjct  364  TRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAA  423 
 
Query  721  TASFMKHLENEQK  759 
            TASFMKHLENEQK 




Score Expect Method Identities Positives Gaps Frame 
536 bits(1380) 0.0 Compositional matrix adjust. 283/287(99%) 286/287(99%) 0/287(0%) +3 
Query  21   QGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKA  200 
            +GTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKA 
Sbjct  486  KGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKA  545 
 
Query  201  FDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQ  380 
            FDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQ 
Sbjct  546  FDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQ  605 
 
Query  381  HKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFAR  560 
            HKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFAR 
Sbjct  606  HKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFAR  665 
 
Query  561  AVDTrleelggerllqlgqgdelCGQEEAFRGWAQAAFQAACETFCVGEDAKAAARDIFS  740 
            AVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAARDIFS 
Sbjct  666  AVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAARDIFS  725 
 
Query  741  PKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKMXQATIRSVENLQAA  881 
            PKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKM QATIRSVENLQ++ 






Score Expect Method Identities Positives Gaps Frame 
402 bits(1033) 4e-135 Compositional matrix adjust. 230/230(100%) 230/230(100%) 0/230(0%) +1 
Query  1    DSAGALGTLRFCVFGLGSRAYPHFCAFARAVDTrleelggerllqlgqgdelCGQEEAFR  180 
            DSAGALGTLRFCVFGLGSRAYPHFCAFARAVDTRLEELGGERLLQLGQGDELCGQEEAFR 
Sbjct  637  DSAGALGTLRFCVFGLGSRAYPHFCAFARAVDTRLEELGGERLLQLGQGDELCGQEEAFR  696 
 
Query  181  GWAQAAFQAACETFCVGEDAKAAARDIFSPKRSWKRQRYRLSAQAEGLQLLPGLIHVHRR  360 
            GWAQAAFQAACETFCVGEDAKAAARDIFSPKRSWKRQRYRLSAQAEGLQLLPGLIHVHRR 
Sbjct  697  GWAQAAFQAACETFCVGEDAKAAARDIFSPKRSWKRQRYRLSAQAEGLQLLPGLIHVHRR  756 
 
Query  361  KMFQATIRSVENLQSSKSTRATILVRLDTGGQEGLQYQPGDHIGVCPPNRPGLVEALLSR  540 
            KMFQATIRSVENLQSSKSTRATILVRLDTGGQEGLQYQPGDHIGVCPPNRPGLVEALLSR 
Sbjct  757  KMFQATIRSVENLQSSKSTRATILVRLDTGGQEGLQYQPGDHIGVCPPNRPGLVEALLSR  816 
 
Query  541  VEDPPAPTEPVAVEQLEKGSPGGPPPGWVRDPRLPPCTLRQALTFFLDIT  690 
            VEDPPAPTEPVAVEQLEKGSPGGPPPGWVRDPRLPPCTLRQALTFFLDIT 




Score Expect Method Identities Positives Gaps Frame 
554 bits(1427) 0.0 Compositional matrix adjust. 318/324(98%) 320/324(98%) 1/324(0%) +2 
Query  32    GLVEALLSRVEDPPAPTEPVAVEQLEKGSPGGPPPGWVRDPRLPPCTLRQALTFFLDITs  211 
             GLVEALLSRVEDPPAPTEPVAVEQLEKGSPGGPPPGWVRDPRLPPCTLRQALTFFLDITS 
Sbjct  808   GLVEALLSRVEDPPAPTEPVAVEQLEKGSPGGPPPGWVRDPRLPPCTLRQALTFFLDITS  867 
 
Query  212   ppspqllrllstlAEEPREQQELEALSQDPRRYEEWKWFRCPTLLEVLEQFPSValpapl  391 
             PPSPQLLRLLSTLAEEPREQQELEALSQDPRRYEEWKWFRCPTLLEVLEQFPSVALPAPL 
Sbjct  868   PPSPQLLRLLSTLAEEPREQQELEALSQDPRRYEEWKWFRCPTLLEVLEQFPSVALPAPL  927 
 
Query  392   lltqlpllqpRYYSVSSAPSTHPGEIHLTVAVLAYRTQDGLGPLHYGVCSTWLSQLKPGD  571 
             LLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVLAYRTQDGLGPLHYGVCSTWLSQLKPGD 
Sbjct  928   LLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVLAYRTQDGLGPLHYGVCSTWLSQLKPGD  987 
 
Query  572   PVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPFRGFWQERLHDIESKGLQPTPMTLVFG  751 
118 
 
             PVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPFRGFWQERLHDIESKGLQPTPMTLVFG 
Sbjct  988   PVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPFRGFWQERLHDIESKGLQPTPMTLVFG  1047 
 
Query  752   CRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREPDNPKTYVQDILRTELAAEVHRVLCLE  931 
             CRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREPDNPKTYVQDILRTELAAEVHRVLCLE 
Sbjct  1048  CRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREPDNPKTYVQDILRTELAAEVHRVLCLE  1107 
 
Query  932   RAHVCL-RDVTMATNVLQTVQRIL  1000 
             R H+ +  DVTMATNVLQTVQRIL 




Score Expect Method Identities Positives Gaps Frame 
500 bits(1287) 9e-170 Compositional matrix adjust. 241/241(100%) 241/241(100%) 0/241(0%) +2 
Query  14    RTQDGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPFR  193 
             RTQDGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPFR 
Sbjct  963   RTQDGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPFR  1022 
 
Query  194   GFWQERLHDIESKGLQPTPMTLVFGCRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREPD  373 
             GFWQERLHDIESKGLQPTPMTLVFGCRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREPD 
Sbjct  1023  GFWQERLHDIESKGLQPTPMTLVFGCRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREPD  1082 
 
Query  374   NPKTYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATNVLQTVQRILATEGDMELDEA  553 
             NPKTYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATNVLQTVQRILATEGDMELDEA 
Sbjct  1083  NPKTYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATNVLQTVQRILATEGDMELDEA  1142 
 
Query  554   GDVIGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVPWAFDPPGSDTNS  733 
             GDVIGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVPWAFDPPGSDTNS 
Sbjct  1143  GDVIGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVPWAFDPPGSDTNS  1202 
 
Query  734   P  736 
             P 
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